TW200817682A - Method of gastric juice protein analysis for stomach cancer diagnosis - Google Patents

Method of gastric juice protein analysis for stomach cancer diagnosis Download PDF

Info

Publication number
TW200817682A
TW200817682A TW96129655A TW96129655A TW200817682A TW 200817682 A TW200817682 A TW 200817682A TW 96129655 A TW96129655 A TW 96129655A TW 96129655 A TW96129655 A TW 96129655A TW 200817682 A TW200817682 A TW 200817682A
Authority
TW
Taiwan
Prior art keywords
gastric
stomach
protein
duodenal
gastric juice
Prior art date
Application number
TW96129655A
Other languages
Chinese (zh)
Other versions
TWI426269B (en
Inventor
Chung-Hsuan Chen
Ping-I Hsu
Wei-Chao Chang
Yuan-Yan Chen
Pei-Jung Frank Lu
Michael Hsiao
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of TW200817682A publication Critical patent/TW200817682A/en
Application granted granted Critical
Publication of TWI426269B publication Critical patent/TWI426269B/en

Links

Landscapes

  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method and biomarkers for detection of a gastroduodenal disease are provided. The method includes the use of mass spectrometry, two-dimensional gel electrophoresis analysis, and/or neural network for analyzing gastric juice samples and detecting elevated and/or suppressed levels of stomach disease-associated proteins and peptides. The biomarkers, peptide fragments, and proteins identified herein can be used in assays and diagnosis kits for a gastroduodenal disease.

Description

200817682 九、發明說明: 【發明所屬之技術領域】 種偵測胃與十二指腸疾病的生物標誌和方法。 【先前技術】200817682 IX. Description of the invention: [Technical field to which the invention pertains] A biomarker and method for detecting gastric and duodenal diseases. [Prior Art]

舌、ft員基因體5十劃完成之後,蛋白質體的研究獲得高产的 二2白f體分析提供—個研究疾病發生的有效H ^用 與病患間全部蛋白質種類和數量有文現S 蛋白質,利用此卿 用;里論叫上其偵測之敏感度和解析度沒有限制,可應 蛋白ΐ體:質ί if本„二蛋白質組成,並產生該測試樣ΐ 於單-測試樣本^自 =;ΐί 白^ 很花時間和金錢,更不用說只有少部是診斷都 基酸序列決定的步驟。、 坪、、、田蛋白質鑑定和/或胺 現階段利用血清樣本進行質譜 ,是血清巾大量的蛋自質於質譜儀巾功ϋ限’部份原 見且不易精確測量。籍由比較正常丄和=患:=罕 5 200817682 并曰别可以應用於卵巢癌和前列腺癌的診斷,雖秋士 =,其精確地分析依然困難重重。利用血清樣本 = 3 ·血清中特異性蛋白含量的天然變 口包 τ同的營養、環境和心理的狀態。;:乂;==於 所產生的變化,某特定蛋白質於血清樣二變ϊ η 容症病患,早期癌症診斷的期望並不 入Μ: Μ成i另—方面’由患處而非血液取得試驗樣本是高度侵 ^能獲得含量較高的腫瘤相關蛋白質,大部份病 田、广击不得已的情況並不願意給予此類的採樣。相反地,從 月^中取得供質譜儀分析的蛋白f /多肽相對簡單許多。 月癌^stomach cancer or gastric cancer; Gc),係為世界二 症ί於早期相#難診斷。胃癌可以存在於胃部-段ί 狀發生W生長成大型的尺寸。在胃癌的早期, ί^ίΐΐΐΐϊ化不良、胃部不適、飯後樓服感、輕微。惡心、 二ϋ在胃癌的進階時期,可能會有血便、呕吐、 物或更f重的疼重。到目前為止,並沒有胃癌良好的生 目前為止,減無可靠的、非侵人性的筛檢 抗;^炉而广言=貞^和監視癌症的一般試驗係測量其腫瘤相關 症生物標諸。此類試驗係測量腫瘤細胞顯著釋出或分 ^於$4中之蛋白質或醣蛋白(glycoprotein)。例如,僅有少部 二白細胞釋出癌胚胎抗原(Carcin〇embryonic antigel1 諸、 tA) ’碳水化合物抗原(CA19_9)或其他目前已知的生物標 6 200817682 進被I::二多癌症特異的或癌症相關的蛋白質在 的量-般隨該疾病的;可二貞,抗原(detec_^ 【發明内容】 生實關倾供胃賴_方法和 度。生物資訊分;^、年夕肽之增加和/或受抑制程 該定義於 指腸疾病之試驗和診斷套袓(kits)。 ,1 μ於胃|4十— 方;。一二施二 =個:定以 :===,本,== 線質量的質譜,並鑑定一譜3 或多個分子係為該胃或十二指腸疾病之生物聽“ ^一们 在另-具體實施例,其係提供—筛 二1=包個含工 =個人類, 該-個或多個質譜與基礎線質量的質^^圖固$ 在本發明之-部份,與基 =線^=疾_1 病歷。 的多肽係被鑑定。該一個或多個多肽之;子係包 200817682 辨識號1-3之胺基酸序列。在本發 相較後,-個或多個多肽增加的 ’與基礎線量 加的量係被鑑H個或多個 t 個蛋白質增 蛋白酶前驅物。 贪白貝之例子係包含α-抗胰 在另一具體貫施例,一個或多個田七一 標誌係被鑑定。例如,十二指腸疾病之生物 的胃癌和胃潰瘍的生物標=^^=,被鑑定為-新 諸被鑑^為包含-胺基酸相,7。目❹個生物標 辨識號1-5之胺基酸序列。 ,、主夕9似相似於選自序列 【實施方式】 本發明之具體實施儀提供胃 指f_較高的敏感度與十二 $比較患者和健康者的試驗樣本並鑑質譜 蛋白質表現量增加和抑制的量。 们或夕個夕肽和 或—個或多個多狀和/ ,疾病的偵測/診斷試驗絲二组工例如此胃與十二指 ^為^癌、胃潰瘍、忙指腸潰瘍和其病 里’進行常態化分析後,達成胃與十二指的 200817682 調整該鑑定之—個或多個生物標誌、於生物 之相對應胃與十二指腸疾病之—個或多個^標諸 係可被應料發展治療和/或猶檢測之標的。 胃液樣本之比較質譜圖譜 + 明之—個或多個具體實施例,係提供—鑑定胃盥 十一彳曰知疾病相關之生物標誌的方法。在一 ^ 在另—具體實施例,制職譜分析=或= 定胃與十m狀生物觀、。在另一具 方法。此外,提供-利用鑑== w以師廷人類病患之胃與十二指腸疾病。 袖入樣本收集的方法收集胃液樣本。—方法係利用 法。内視鏡吸取胃液,亦可利用其他非内視鏡的方 I與十二指腸疾病而言’獲得胃液樣本相對 二=ί ’ Γ數以百萬的患者和一般受測者係進行年度 兄檢查。亦可利用不需内視鏡的非侵入性方法以收隼胃 ,本/例如/收集胃液樣本時利用—非侵人性的線繩試驗After the completion of the phenotype of the tongue and the ft, the proteosome study yields a high-yield two-two white body analysis to provide an effective study of disease occurrence and the total protein type and quantity of the disease. Use this Qing; the theory is called the sensitivity and resolution of the detection is not limited, can be protein corpus callosum: quality ί if this „ two protein composition, and produce the test sample 单 single-test sample ^ from =;ΐί 白^ It takes a lot of time and money, not to mention that only a few are the steps to determine the sequence of the acid. The protein identification and/or amine use of serum samples for mass spectrometry is a serum towel. A large number of eggs are self-contained in the mass spectrometer. It is not easy to accurately measure. It is compared with normal 丄 and = suffering: = 罕5 200817682 and screening can be applied to the diagnosis of ovarian cancer and prostate cancer, although Qiu Shi =, its accurate analysis is still difficult. Use the serum sample = 3 · the natural protein content of the specific protein content in the serum, the same nutritional, environmental and psychological state.;: 乂; = = produced Change, a specific protein In patients with serum-like dimorphism, the expectation of early cancer diagnosis is not a problem: Μ成i---the test sample obtained from the affected area instead of the blood is highly invasive and can obtain a higher content of tumor-associated protein. Most of the diseased fields and the wide-ranging cases are not willing to give such sampling. On the contrary, it is relatively simple to obtain the protein f/polypeptide for analysis by mass spectrometer from the moon ^. cancer cancer or gastric cancer Gc), which is the world's second syndrome. It is difficult to diagnose in the early phase. Gastric cancer can exist in the stomach-segment, and grows into a large size. In the early stage of gastric cancer, ί^ίΐΐΐΐϊ is bad, stomach discomfort, After meals, the feeling of the building is slight, and the nausea and sputum may be in the advanced stage of gastric cancer. There may be bloody stools, vomiting, or heavy weight. So far, there is no good stomach cancer so far. There is no reliable, non-invasive screening resistance; the general test for monitoring cancer and measuring the cancer is related to the biomarker. This type of test measures the significant release or distribution of tumor cells. $4 of protein or For example, only a few of the two white blood cells release the cancer embryo antigen (Carcin〇embryonic antigel1, tA) 'carbohydrate antigen (CA19_9) or other currently known biological standard 6 200817682 into I:: two The amount of multiple cancer-specific or cancer-associated proteins is generally associated with the disease; can be diazepam, antigen (detec_^ [invention content] Shengshiguan supply of stomach _ method and degree. Biological information points; ^, year The increase and/or inhibition of the compound peptide is defined in the test and diagnostic kits for intestinal diseases. 1 μ in the stomach | 4 — - square; One or two Shi 2 = one: set to: ===, Ben, == line mass mass spectrometry, and identify a spectrum of 3 or more molecular systems for the stomach or duodenal disease of the organism to listen to "^ one in another-specific In the embodiment, it is provided that - sieve 2 1 = package contains = personal, the quality of the mass spectrum and the quality of the base line is in the - part of the invention, and the base = line ^ = disease_1. The polypeptide is identified. The one or more polypeptides; the sub-packages 200817682 The amino acid sequence of identification numbers 1-3. After the present invention, the one or more polypeptides are increased. 'The amount added to the baseline amount is identified by H or more t protein protease precursors. Examples of greedy white shells contain alpha-anti-pancreas in another specific example, one or more Tianyiyi signs The system is identified. For example, the biomarker of gastric cancer and gastric ulcer in the organism of duodenal diseases = ^^=, identified as - the new ones are included as containing the amino acid phase, 7. The target is identified by a biomarker number 1- The amino acid sequence of 5, , and the like, are similar to the selected sequence. [Embodiment] The specific embodiment of the present invention provides a higher sensitivity of the stomach finger f_ Twelve $ compare the test samples of patients and healthy people and determine the amount of protein expression and the amount of inhibition of the mass spectrometry. They may or may not have one or more polymorphisms and /, disease detection / diagnostic test silk two For example, after the normalization analysis of the stomach and the twelve fingers ^ for the cancer, the stomach ulcer, the busy finger ulcer and the disease, the 200817682 of the stomach and the twelve fingers is adjusted to adjust the identification of one or more biomarkers. One or more of the corresponding strains of the stomach and duodenal diseases may be developed for treatment and/or heal detection. Comparison of Gastric Juice Samples Mass Spectrometry + One or More Specific Examples , providing a method for identifying biomarkers associated with disease and stomach disease. In another embodiment, the composition spectrum analysis = or = fixed stomach and ten m-like biological view, in another In addition, provide - use the use of == w to the stomach and duodenal diseases of human patients in the court. Sleeve sample collection method to collect gastric juice samples. - Method is to use the method. Endoscope to absorb gastric juice, can also use other Non-endoscopic side I and ten In the case of duodenal diseases, 'getting a sample of gastric juice relative to two = ί ' Γ millions of patients and the general subject are undergoing annual brother examination. Non-invasive methods without endoscopy are also available to collect the stomach , this / for example / when collecting gastric juice samples - non-invasive wire rope test

C (T^ng/ eH非侵入性的線繩試驗係應用於胃幽門螺旋桿菌 受ίϊί田斷以幫助流行病學的研究以評估無症狀 2,二幽,旋桿菌情況。另—獲得胃液樣本的例子包括 - 40 囊’其包含—沿著吸收紙片的穿孔塑膠覆蓋和 苴停留於田長^至内部膠囊的尼龍線,吞°燕該膠囊並使 二ΐί, 〇刀里以使吸收紙片飽合吸收胃液,接著,拉 =月I線由胃腔移出該膠囊並由該吸收紙片獲得胃液。 月液係包含數個化合物’包含鹽酸 因子、多肽、抑酸和電解質等等此夕卜ί可 ί i於液成份 '胃及十二指腸的逆流包含膽汁、和 ;叉貝月土的免疫調控因子或血液及來自於胃癌的致癌 9 200817682 。該胃液樣本係計劃地利用於 因為胃液樣本中蛋白質或多肽的數的^譜分析, 非ΪΧΞ3境=了=素,墙的以ΐ 中白質不能存在,我們假 大口 in刀的蛋白質具咼分子量古 時典型質譜儀的解析度非常有限,二於高質量 蛋白質是相當困難的。然而 圍内分辨 樣本的例子,較短 :忠白貝被扁化分解,如胃液 :,相對地可以獲得高解析度的夕多肽質ΐ定容易 ^本發明藉由提供多狀體㈣tid〇mic)^蛋所產 搜索生物標諸以做為疾病之診斷。 、體的刀析於 做為 分佈態樣以 可祐刹::u 的疋,猎由本發明方法鐘定之多欣# ΐί蛋消化而製造,某些多肽的含量係與 未詳知。然而’多種多狀之比較測定對編 型:二,多數肽:合胃4中 並與不同的胃與十二相=發=* 和特異的胃胃,的特殊質譜 十二指勝膝和其他結腸相齡丨 200817682 方法分析。 可發現胃癌病患的胃液山 (較不酸)和較高程度之华乂1 又人具較馬之PH值 個或多個具體實施例,f s 據本發明之- 於此,二與二指腸疾病之偵測與診斷 肽片段和蛋白並成功地鑑定胃癌相關之多 敏感性和可#i果亦暗指胃液分析優於血清分析根據其 ( 上艮據本發明之—個❹個具體實施例,當收 :=蛋白質純化以萃取胃液樣本之蛋白質和/或多肽^移广 ί:ί你,’離心可被利用於移除污染物。此》,磁性2 i粒:係為-簡單;快速且容易的方式由胃液樣本中 ^ ^他蛋白質卒取的方式亦被利用,包括鑽石奈米粒早 、HPLC、離子交換管柱色層分析、二維凝膠、、西方:去 毛細管,等等,蛋白質萃取方法並不限於上述。法、 一貫施例係利用基質—輔助雷射脫附離子化 :^1X_aSS1Sted laSer de卿tion/ion h儀(time_of_fllght mass spectrometer; TOF-MS)以庐得吝肢/疋 ^質之質譜。藉由maldi-tof-ms,-個質譜分G可於數秒 =内獲得。一般而言,經由MALDI,僅單一或雙電荷可被獲 付,该結果圖譜較其他種類之質譜明顯地簡易。然而,其他2 類之質譜儀亦被利用包括,但不受限於上述質譜,電噴霧質譜 儀(electrospray mass spectrometry)、脫附電噴霧質 ^ (desorption electrospray mass spectrometry)、雷射誘發原聲&附 質譜儀(laser induced acoustic desorption mass spectrometry)和 其他。各式的質譜儀亦被利用。 電喷霧屬於溫和的離子化方式,並容易在大蛋白質產生卢 電荷,使其適於分析具高分子量之蛋白質和多肽。雖然電喷^ 質譜儀通常很複雜,然而多肽質譜態樣並不如蛋白質態樣複 200817682 f ’因此電喷霧質譜儀可利用此優點進行分 &,多肽具有少於3之電荷。根據質量選擇、離^ '而 磁力部份和傅葉爾轉換(F0urier transf〇rm),質 η 換。因為傅葉爾轉換質請儀具有非常 解曰^ >2_00),其係為一測量質譜間差異;常 、多肽和蛋白質的質譜態樣係可被用於分辨胃痒 般測武樣本。質譜態樣亦可被用於分辨胃潰^ 般無潰瘍人類受測者賴本。#胃料本和一C (T^ng/eH non-invasive cord test was applied to Helicobacter pylori in the stomach to help epidemiological studies to assess asymptomatic 2, dioxin, bacillus. Another - get gastric juice samples Examples include - 40 capsules' which contain - a plastic line covering the perforated plastic along the absorbent sheet and a nylon thread that rests in the length of the field to the inner capsule, swallowing the capsule and allowing the capsule to saturate the absorbent sheet. The gastric juice is absorbed, and then the pull-month I line is removed from the stomach cavity and the gastric juice is obtained from the absorbent sheet. The monthly liquid system contains several compounds 'containing hydrochloric acid factors, polypeptides, acid suppression and electrolytes, etc. ί i in the liquid component 'gastric and duodenal reflux contains bile, and; immunoregulatory factor of the moon and moon, and blood and cancer from the stomach cancer 9 200817682. The gastric juice sample is intended to be used in the gastric juice sample protein or peptide The spectrum analysis of the number, the non-ΪΧΞ3 environment = the = prime, the wall of the ΐ ΐ white matter can not exist, we have a large mouth in the knife protein, the molecular weight of the ancient time, the typical mass spectrometer resolution is very limited, two It is quite difficult to use high-quality protein. However, the example of distinguishing samples within the circumference is shorter: the baibai shell is decomposed by flattening, such as gastric juice: relatively high-resolution 夕 polypeptide can be obtained. The search biometrics produced by the polymorph (4) tid〇mic) eggs are used as a diagnosis of the disease. The body of the knife is analyzed as a distribution pattern to the blessing of the brake::u, the hunting is made by the method of the present invention, Zhong Ding, and the content of certain polypeptides is not known. However, 'multiple polymorphisms are compared to the pairing: two, most peptides: combined with stomach 4 and with different stomachs and twelve phases = hair = * and specific stomach and stomach, special mass spectrometry twelve fingers win knee and other Colon phase age 丨 200817682 method analysis. It can be found that the gastric juice mountain (less acid) of the gastric cancer patient and the higher degree of Huayu 1 have a PH value or a plurality of specific examples, fs according to the present invention - here, two and two fingers The detection and diagnosis of intestinal diseases and the successful identification of peptide fragments and proteins and the successful identification of gastric cancer are more sensitive and can also be attributed to the analysis of gastric juice than the serum analysis according to it. For example, when: = protein purification to extract the protein and / or peptide of the gastric juice sample ^ ί : ί you, 'centrifugation can be used to remove contaminants. This, magnetic 2 i grain: is - simple; A quick and easy way to use the protein in the gastric juice sample is also used, including diamond nanoparticle early, HPLC, ion exchange column chromatography, two-dimensional gel, Western: decapillary, etc. The protein extraction method is not limited to the above. The method and the consistent application system utilize the matrix-assisted laser desorption ionization: ^1X_aSS1Sted laSer deqingtion/ion h (time_of_fllght mass spectrometer; TOF-MS) to obtain the prosthetic limb Mass spectrometry by massi-tof-ms, a mass spectrometer G can be obtained in a few seconds =. In general, only one or two charges can be obtained via MALDI, and the resulting map is significantly easier than other types of mass spectrometry. However, other two types of mass spectrometers are also utilized, However, it is not limited to the above mass spectrometer, electrospray mass spectrometry, desorption electrospray mass spectrometry, laser induced acoustic desorption mass spectrometry, and the like. Various mass spectrometers are also used. Electrospray is a mild ionization method and is easy to generate a large charge in large proteins, making it suitable for the analysis of proteins and peptides with high molecular weight. Although EFI mass spectrometers are usually very Complex, however, the mass spectrometry of the peptide is not as good as the protein state. 200817682 f 'Therefore, the electrospray mass spectrometer can use this advantage to divide & the peptide has a charge of less than 3. According to the mass selection, the magnetic part And the Fourier transform (F0urier transf〇rm), the quality η change. Because the Fourier transform quality instrument has a very solution ^ > 2_00), Mass difference is the measured one; Chang, mass spectrometry-based aspect of polypeptides and proteins can be used to resolve gastric Wu itch-like sample measured. The mass spectrometry can also be used to distinguish gastric ulcers from ulcer-free human subjects. #胃料本和一

C ,樣本之比較質譜亦可细於⑽或n二 f癌症,應直接比較收集自癌細胞的 而’自癌㈣包獲得樣本的過程是侵入性的,且 而,收集自疾病位置、血清樣本、血难揭 =扪^ 樣本之細胞的試驗樣本亦被糊於本’質=和其他 較 疾二巧二各二狀;r/的量曰:二料 和其他生㈣錄體%被^ 路程式 得的數據’以於質譜中比較」===:大量獲 樣分析可被施行於正常者和病患的樣本/又°亥同 胃液樣本的二維電泳 a在另一替代之具體實施例,施行二維電泳以分 P吊I ΐ提異。除了分子量,二維電泳係藉由 析僅藉t分倾紅射躲化,細質譜分 维不同胃與十二指腸疾病患者胃液樣本的二 1“果^見3種不同的條帶態様,包含基礎條帶態様、特 12 817682 =帶態様蝴雜_。—罐㈣果如第u圖 比較病患樣本之侔鹛能& 康者樣本基礎線之二維條帶的絲或強度與健 量,其係藉由二維凝膠上^讀定異常蛋白質 蛋白的態樣係被利用於分辮1^度所减。例如,二轉膠 驗樣本。二維轉蛋自樣本和—般健較測者的試 本和正常非胃潰瘍健康受i者^^。=辮胃潰癌f者的樣 腸病。患的樣本和健康者的樣本。、7 外’亦比較胃十二指 並^維凝雜帶態樣, 個或多個蛋白質條帶^為^I,#、帶之強度係暗指其一 达。藉由自二維ΐ膠腸疾狀良好生物標 或多個蛋白質條帶的特=由多酸 可以發現,來自健康者和+二沪腊、、析 様的頻率相對較低’兩者皆約為6;,:以5》:態 f;f患门縣之特殊條帶態様的頻率則為:f2 7 i * 以做為胃潰瘍和胃癌之特殊蛋白質生物H貝條一可被分析 我們也魏,胃赫和胃航t、胃 者明顯地增高(約1·〇6 mg/ml和約2 、/又車乂健康 mg/ml,個別地),且十二_潰瘍患者具::=48 質濃度與健康者相較(約〇.26 mg/mlv低^液^蛋白 :卜奇老化Λ為影響胃液蛋白質漠度之二子此 =2'^η^32·9(95^㈣以 鐘定自胃液之生物標誌及其應用 鑑定自本發明方法之生物標該係可適用於胃與十二指腸疾 13 200817682 病之診斷試驗或篩檢套組。此外,該鑑定自本發明方法之生物 標誌,可應用於設計胃與十二指腸疾病之治療方式或胃與十 二,腸疾病治療方式之標的。一組特殊的多肽可做為可靠之疾 病#斷有價值之生物標誌。例如,本發明係提供胃液中特殊的 多肽和蛋白質做為胃癌診斷之生物標諸,包含多肽gig? m/z、 多肽 2387 m/z、多肽 3573 m/z、多肽 2573 m/z、多肽 4132 m/z、 α-抗胰蛋白酶前驅物和其他。 這些多肽的胺基酸序列係列舉為序列辨識號船S ·· 。多C, the sample comparison mass spectrum can also be finer than (10) or n-f cancer, which should be directly compared with the cancer cells collected from the cancer (four) package. The process of obtaining the sample is invasive, and is collected from the disease location, serum samples. The blood sample is difficult to be revealed = 扪 ^ The sample of the sample of the cell is also smeared in this 'quality= and other more quarantines two; two types of r / 曰: two materials and other raw (four) recorded body% ^ road Program-derived data 'Compared in mass spectrometry' ===: A large number of sample-analyzed samples that can be applied to normal and patient samples/two-dimensional electrophoresis of a sample of gastric juice in a different embodiment , performing two-dimensional electrophoresis to divide P I I ΐ to improve. In addition to the molecular weight, the two-dimensional electrophoresis system uses only the t-point oblique red-shot to hide, and the fine-mass spectrometry divides the gastric juice samples of patients with different stomach and duodenal diseases into two different bands, including three different strip states, including the basic strip. Band state 様, special 12 817682 = band state 様 杂 。 。 。 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐 罐By using a two-dimensional gel to read the abnormal protein protein, the pattern is used to reduce the degree of bifurcation. For example, a two-transfer test sample. Two-dimensional transfer from the sample and the general tester The test and the normal non-stomach ulcer health are affected by ^ ^. = 辫 stomach ulcer cancer f-like enteropathy. The sample of the patient and the sample of healthy people., 7 outside 'also compare the stomach and fingers and ^ Wei coagulation With the appearance of the sample, one or more protein bands ^ is ^I, #, the intensity of the band implies one of them. By the two-dimensional silicone gut good biomarker or multiple protein bands special = It can be found from polyacids that the frequency from healthy people and + two Hu La, and sputum is relatively low 'both are about 6;,: to 5: state f; f suffering from the county The frequency of the special strip state 様 is: f2 7 i * as a special protein organism of gastric ulcer and gastric cancer H. It can be analyzed. We also Wei, stomach and stomach hang, stomach is obviously increased (about 1 · 〇 6 mg / ml and about 2, / rut health mg / ml, individually), and twelve _ ulcer patients with:: = 48 Qualitative concentration compared with healthy people (about 26.26 mg / mlv low ^液^蛋白: Buqi aging Λ is the second son of the gastric acid influencing gastric juice. This = 2'^ η^32·9 (95^(4) is the biomarker of Zhongding from gastric juice and its application is identified from the biomarker of the method of the present invention. The system can be applied to a diagnostic test or screening kit for gastric and duodenal diseases. In addition, the biomarker identified from the method of the present invention can be applied to the treatment of gastric and duodenal diseases or the stomach and twelve. The standard of treatment of intestinal diseases. A special group of polypeptides can be used as a reliable disease. A valuable biomarker is provided. For example, the present invention provides specific polypeptides and proteins in gastric juice as biological markers for diagnosis of gastric cancer, including polypeptides. Gig? m/z, peptide 2387 m/z, polypeptide 3573 m/z, peptide 2573 m/z, peptide 4132 m/z, α-antitrypsin precursor and others. The amino acid sequence series of these peptides is given by the serial identification number ship S ··.

,2187,、多肽2387 m/z和多肽3573 m/z(序列辨識號腿: 1-3)的1被發現與一般健康者相較其於胃癌病患中較低。缺 而二多肽2573 111/2和多肽4132111/2(序列辨識號船3:4_5) 的量被發現與一般健康者相較其於胃癌病患中增高。 多狀2187 111/2(序列辨識號:1111101«^1^^)和多 ^387 m/z(序2,腿_p鑛卿EA)係為騰 蛋白S#原之一部份。多肽3573 m/z(序列 ^^_νί^®Ε〇α(_Ρδνι^Ό #、為—亮紐拉ς 結構 蛋白(leucme ziPper protein)之多肽片段。此 抑制量的重要性仍在研究中。 主夕服乃杈又 多肽2573 m/z(序列辨識號.4 DAHKSEVA_LGEE_VL)係為一白蛋白之多肽片段。普遍 認為’癌症病患具較高出血的可能性使白蛋自由血f中進又 蛋白在^酸性之胃忙指腸環境下㈣化 刀^成小的夕肽且此類多肽和癌細胞交互作用轉持高 而受本發明之方法偵測並於胃液中觀察到。該多肽4132 m/z(序 列 辨識 號 · 5 =ρ^_^_Ε_^ΡΙ^Μ(}κννΝρτ(^κ)表現量 增加的1的重要性仍在研究中。 所m自胃癌樣本二維電泳特殊條帶態様條帶之蛋白 貝體刀析和胺級序齡油示,α—抗胰蛋㈣前驅物係為 14 200817682 ;ί;=癌t本特殊條帶之主要蛋白質,如第18圖之B1 二見高= 蛋 的胃癌的生物標i。蛋白哺驅物係可作為早期和進階 受I2 由 患有,二指腸疾病之人類 本,來自於收隼之他揭生物―4。收集胃液試驗樣 化。木目於H‘樣本的多肽和蛋白質係可被部份地純 藉由各式的偵測方法,與胃盥 諸的量係可被篩選。例如相關之生物標 特徵態樣利用於篩選胃十一指=貝,月液,樣係可作^ ^ 可利用於篩檢ΐ盘ΐϊ具有兩於_序列特徵之多肽係 由本發明之方ir胃ϋ生和/或胃癌與其他的應用。藉 斷和胃與十二指腸疾病診斷發現係提供-簡易胃癌診 量^節此類生峨表現 之酵素和蛋白質相白關貝月4之生物標認、鑑定於此 此外’許多生物t in病之治療或偵測之可能標的。 時作為-疾病診;:可!二、酵素和多肽的量化偵測係可同 較受測者樣本的基礎線量相 能為胃與十二試驗樣本係可 劳注如果该喊驗樣本的生物標誌的量 15 200817682 和基礎線的量相同,則該受測者係為陰性。 實施例 本發明以下列實施例做進一步闡明,但發明的範圍不夸於此眼1 of 2187, polypeptide 2387 m/z and polypeptide 3573 m/z (sequence recognition leg: 1-3) was found to be lower in patients with gastric cancer than in general health. The amount of the second polypeptide 2573 111/2 and the polypeptide 4132111/2 (sequence identification number 3:4_5) was found to be increased in comparison with the general health. Polymorphism 2187 111/2 (sequence identification number: 1111101 «^1^^) and multiple ^ 387 m / z (order 2, leg _p mineral EA) is a part of the original protein S #. Peptide 3573 m/z (sequence ^^_νί^®Ε〇α(_Ρδνι^Ό#, a polypeptide fragment of the leucme ziPper protein. The importance of this inhibition is still under investigation. Xifu Naiqi and peptide 2573 m/z (sequence identification number.4 DAHKSEVA_LGEE_VL) is a polypeptide fragment of albumin. It is generally believed that 'the possibility of higher bleeding in cancer patients makes the white egg free blood f into the protein. In the stomach of the acidic stomach, (4) the sputum into a small peptide and the interaction between the polypeptide and the cancer cells is high and is detected by the method of the present invention and observed in gastric juice. The polypeptide 4132 m The importance of /z (sequence identification number · 5 = ρ^_^_Ε_^ΡΙ^Μ(}κννΝρτ(^κ)) is still under study. The m-specific special band state of gastric cancer samples from two-dimensional electrophoresis The protein shellfish and the amine-grade oil of the band show that the α-anti-pancreatic egg (four) precursor system is 14 200817682; ί; = the main protein of the special band of cancer t, as shown in Figure 18, B1 = egg biomarker of gastric cancer i. protein feeding system can be used as early and advanced by I2, human suffering from duodenal diseases Ben, from the collection of his biological disclosure - 4. Collecting gastric juice test samples. The peptides and protein lines of the woody H' sample can be partially purely by various detection methods, with the amount of stomach cramps The system can be screened. For example, the relevant biomarker features are used to screen the stomach eleven fingers = shellfish, the moon liquid, and the sample system can be used for screening. The polypeptide can be used for screening. The invention of the prescription ir stomach and/or gastric cancer and other applications. The diagnosis and diagnosis of gastric and duodenal diseases are provided - the diagnosis of simple gastric cancer ^ The enzymes and protein of this kind of oyster performance are white Biometric identification, identification, and other possible treatments or detection of many biological diseases. When used as a disease diagnosis;: Yes! Second, the quantitative detection of enzymes and peptides can be compared with the sample of the subjects. The basic line phase energy can be used for the stomach and the twelve test sample. If the amount of the biomarker 15 of the test sample is the same as the amount of the baseline, the subject is negative. EXAMPLES The present invention was implemented as follows Examples are further clarified, but the scope of the invention is not This eye

囷l^nsteruetrap广一般而言,受測者,例如人類受測者,禁 隔夜以劇呆精確性和避免在樣本分析時的複雜性。其他非^ 鏡的方法亦被利用。例如’-高度吸收力的線繩纏&於一且重 量的膠囊内部。P雌吞鱗職並於15分鐘後由胃部取^出。 該線段之遠端係被剪裁以做為胃液樣本。各式收集胃液的方法 接著施行定期上胃十二指腸管道的檢視,並由較大彎曲之 竇室(antrum)獲得活體組織切片行快速尿素酵素分析以決定 丑砂/oW感染情形。對同意進行地形組織病理研、究 (topographical histopathological study)的受測者採取額 組織以行胃部的組織檢視。於巾f室(midantmm)(幽門腺 和中體(middle b〇dy)(胃底腺區)較小和較大彎曲的部份 個樣本。該活體喊樣本以1G%的緩衝福馬林固定、以石於 包埋並切片。該切片以H&E染色。該切片進行盲 ^ (intestinal metaplasia))。為了調整臨床的特徵 者下列的資料:年齡、性別、胃癌家族歷史、 情形。 診斷檢視。藉由升_ Sydney純評估胃炎動 浸潤(副rophil inflltration)、單核細胞細胞浸潤(m〇n〇nudear cell infiltmtion)、腺體萎縮(glandular atr〇phy)和小腸變性生長 ,記錄每個受測 抽煙歷史和飲酒 豈列2 :收集胃液檨太 16 200817682 後 測量儀(glass_electrodepHmeter)收集之 4°c,離心^ ?11值。該收集之胃液樣本接著於10,0⑻xg, 清液並儲在鐘以移除細胞破片和汙染物。平均分配該上 氫氧化鈷由^70它直至進一步的試驗分析。以2μ1150 mM的 需的pH值/約1〇μ1離心後的胃液樣本上清液以調整至一所 本,之—個或多個具體實施例,當收集該胃液樣 並移除、、亏蛋白質純化以萃取該胃液樣本的蛋白質或多肽囷l^nsteruetrap In general, subjects, such as human subjects, are banned for nighttime accuracy and avoid complexity in sample analysis. Other methods of non-mirror are also utilized. For example, the '-a highly absorbent strand is wrapped around the inside of a heavy and heavy capsule. P female swallowed the scale and took it out of the stomach after 15 minutes. The distal end of the line segment is clipped for use as a sample of gastric fluid. Various methods of collecting gastric fluids are followed by periodic examination of the upper gastroduodenal duct, and biopsies obtained from the larger curved antrum are subjected to rapid urease analysis to determine the ugly/oW infection. Subjects who consented to a topographical histopathological study were examined with a tissue for the stomach. Part of the small and large curved part of the midantmm (the pyloric gland and the middle b〇dy). The living body shouting sample is fixed with 1G% cushioning formalin. The stone was embedded and sectioned. The section was stained with H&E. The section was subjected to intestinal metaplasia). In order to adjust the clinical characteristics, the following data are included: age, gender, family history of gastric cancer, and situation. Diagnostic review. Each of the tested subjects was evaluated by Ascending _ Sydney pure evaluation of gastrient infiltration (rophilic inflltration), monocyte infiltration (m〇n〇nudear cell infiltmtion), glandular atr〇phy, and small intestine degeneration. Smoking history and drinking list 2: Collecting gastric juice 檨 too 16 200817682 After measuring instrument (glass_electrodepHmeter) collected 4 °c, centrifuge ^ 11 value. The collected gastric fluid sample was then passed at 10,0 (8) xg, and stored in a clock to remove cell fragments and contaminants. The upper cobalt hydroxide was evenly distributed from ^70 to further experimental analysis. The gastric juice sample supernatant after centrifugation at a desired pH of about 1150 mM / about 1 〇 μ1 is adjusted to one, one or more specific examples, when the gastric juice sample is collected and removed, the protein is deficient Protein or polypeptide purified to extract the gastric juice sample

ΪΓ 。例如,藉由奈米粒子珠球(nanoparticle beads) 進—步的蛋白質萃取。 ’ 切弟為一收集胃液樣本以行質譜分析的範例圖表介 ί ί ^發日狀—具體實關。該胃祕本係結合銅磁 ^未結合的部份。結合的部份可藉由一緩触或一^而 中=μ1的析出緩衝液(elution buffer),在磁力消失之後被析 使用之析出緩衝液係為5〇〇/0之乙腈(acet〇nitrile)。 各式表面修飾的磁性珠球,例如C8、C18、磁性奈米粒子、 鑽石奈米粒子或其他金屬奈米粒子係可被利用。第4圖介紹胃 液樣本收集於50%乙腈析出緩衝液之中並準備好 質譜 析。部份蛋白質純化、HPLC、離子交換、二維凝 點和毛細管電泳係使癌症和非癌症病患間的質譜比較更簡易。Oh. For example, protein extraction by nanoparticle beads. 'Changdi is a sample chart for collecting gastric juice samples for mass spectrometry analysis. The stomach secret is combined with the copper magnetically unbound portion. The bound part can be separated by a slow buffer or a meso = μ1 elution buffer, and the precipitation buffer used after the magnetic force disappears is 5 〇〇 / 0 acetonitrile (acet〇 nitrile) ). Various surface modified magnetic beads, such as C8, C18, magnetic nanoparticles, diamond nanoparticles or other metal nanoparticles, can be utilized. Figure 4 shows that the gastric sample is collected in 50% acetonitrile precipitation buffer and ready for mass spectrometry. Partial protein purification, HPLC, ion exchange, two-dimensional gel point and capillary electrophoresis systems make mass spectrometry between cancer and non-cancer patients easier.

U0個連續健康受測者(HSs)、39個胃潰瘍病患(GU)、38個 =二指腸潰瘍病患(DU)和31個胃癌(GC)病患係參與本2D凝 ^電泳研究。該健康受測者招募於健康檢查門診且不^具胃十二 指腸疾病病史。健康受測者的内視鏡檢查結果為正常或僅呈現 輕微胃炎。病患排除原則包含於本研究前4週内質子幫浦抑制 背J、H2受體頡頎劑(¾ receptor antagonists)或非類脂醇抗發炎藥 17 200817682 物的使用、兩種月十一指腸病灶的共同存在、上胃十二指腸 血的表現和嚴重系統性疾病的共同存在。 曰出 藉由内視鏡檢查確認胃潰瘍和十二指腸潰瘍的診斷,一 指具有於直涵5公釐或大於5公釐之環形黏職傷且日^ 顯定義之潰瘍。#由在麟前張開—己知寬度之活體组= 鉗子測量該潰瘍的尺寸。 、巧 精由組織學確s忍月癌病患並根據Lauren的分類方法八来自发 腸型胃癌(n=19)、擴散性胃癌(n=9)和混合性胃癌(n=3)二 後胃癌病患(n=27)腫瘤侵害的程度根據日本胃癌1研究學會^τ Japan Research Society for Gastric Cancer)提出的標準進一曰牛 e 分為f期*進_胃癌樣本。本研究經高雄榮民總醫院醫“二 究委員會核准。全部病患和控制組係知悉同意。 近期研究指出,腸型胃癌的發生為—多重步驟事件,1 ^(superficial gastritis) > f ^(atr〇ph;' gastritis)、小腸變性生長(intestinal⑽邮以㈣、發】私 (dysplasia)演變成惡性腫瘤,透過累積的多重遺傳改x ^ = 質富含量、結構或功能的改變。關於擴散性胃癌,1黏附八 (adhesion molecules) ^ ^ i^li^l^(E-cadherb) > 素(catenin)和膜聯蛋白-7 ( annexin_7)的喪失亦參與其癌化、尚 程。 w、⑴ k 因為胃癌發生過程中,胃部蜂窩狀上皮細胞 將導致胃液成份改變,於此所描述之胃液蛋白質究^ 發現新型腫瘤特殊標誌以篩檢胃惡性腫瘤之」巨大捉仏 外,各式胃與十二指腸病患胃液之蛋自質濃度和成& ^ 於發現新型疾病的生物標諸。 m用 藉由Bradford方法(21)決定胃液之全部蛋白質濃产。一— 之蛋白含量(約5Gpg每片膠)係被使用於二維電泳$二= 蛋白質墨點藉由質譜加以分析鑑^。―含有約5 樣本以丙酮(1至2Wv)於約_2Gt:沉殿約2個小時, 18 200817682 液於10,000xg,4°C,離心10分鐘。該沈澱物以再水合溶液(9M 尿素,35mM Tris,42 mM DTT,2% CHAPS,0.66% SDS,2% IPG緩衝液,微量溴酚藍)混合,並加入於固定的pH梯度IPG 膠條,11 公分,非線性,pH 4-7 (Amersham Phamacia Biotech, Immobiline Dry-Strip, Uppsala, Sweden)在 30V 條件下進行隔夜 覆水反應。 透過第一維和第二維凝膠電泳施行二維電泳。利用商業上 可得的、專門的設備,例如,IPGphor (Amersham Phamacia Biotech ),施行第一維凝膠分離。蛋白質被連續地集中於約 200V,約1個小時、約500V,約1個小時、約1000V,約1個 小時。接著施行一約1000V至8000V之梯度約30分鐘。接 著施行8000V之繼續集中約8個半小時以於IPGphor獲得一 總量70kVh。 於第二維,該PG係平衡於50 mM tris-CL, pH 8.8, 6M尿 素,30%甘油,1%DDT,和溴酚藍約12分鐘,並接著於50 mM tris-CL,pH 8.8,6M 尿素,30% 甘油,1.2%SDS, 2%iodoacetamide,和溴酚藍約12分鐘。將該膠條置於15%梯 度聚丙_胺凝膠平板之上(190 X 140 X 1mm)且施行該凝膠電 泳至隔天。該凝膠係以硝酸銀染色。 藉由一南解析度的掃描器(GS-710 Calibrated Imaging Densitometer,Bio-Rad)紀錄凝膠中蛋白質之態樣為數位影 像。以PDQuest軟體(Bio-Rad)做凝膠影像比對。 此外’在自二維凝膠萃取該蛋白質之前,以豬的胰蛋白酶 (Promega,Madison,USA)消化分解該凝膠片段可理想地施行 膠内膜蛋白S#之消化分解。以二氟乙酸(trifluoroacetic acid)和 乙腈(acetonitrile; ACN)萃取該結果的消化分解的多肽片段並 將其行質譜分析以決定其質量和胺基酸序列。在質譜分析之 鈾 ’ $亥夕狀係以 ZipTipC18(Millip〇re,Bedford,USA)純化,根 據該製造者的說明書。 19 200817682 實施例4:質譜儀分妍 於基質-輔助雷射脫附離子化飛行時間質譜儀(1^^]〇1 TOF-MS)分析,一般而言,以一含有2,5—二羥基苯甲酸 (2,5-dihydroxybenzoic acid) (5〇ηιη〇ι/μΐ 於 5〇% 乙腈)和石粦酸 (phosphoric add)(終濃度約為〇·4%)之約1 μ1混合液混合約! μΐ之析出的胃液樣本。其他已知適合製備蛋白質離子之基質 亦以相同之絲試驗。接著,約丨μ1該結果混合物被製成 4^墨f於MALDI無染色之鋼製樣本盤上並將其於室溫中風 乾。藉由一修飾自ABI Voyager DE_STR MALDI-T0F質譜儀U0 consecutive healthy subjects (HSs), 39 gastric ulcer patients (GU), 38 = duodenal ulcer patients (DU), and 31 gastric cancer (GC) patients were involved in this 2D gel electrophoresis study. The healthy subject was recruited at a health check-up clinic and did not have a history of gastroduodenal disease. Endoscopic examinations of healthy subjects were normal or showed only mild gastritis. The patient exclusion principle was included in the prosthetic pump to inhibit the use of back-J, H2 receptor antagonists (3⁄4 receptor antagonists) or non-lipid alcohol anti-inflammatory drugs 17 200817682 within the first 4 weeks of the study, two months 11 fingers The coexistence of intestinal lesions, the presence of upper gastric duodenal blood, and the common systemic disease.曰 诊断 诊断 藉 藉 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃 胃#由开前前—The living group with the width known = the pliers measure the size of the ulcer. Qiaojing is determined by histology and is based on Lauren's classification method. Eight from the intestinal type of gastric cancer (n=19), diffuse gastric cancer (n=9) and mixed gastric cancer (n=3) The degree of tumor invasion in patients with gastric cancer (n=27) is based on the criteria proposed by the Japanese Society for Gastrointestinology 1 (the Japanese Society for the Study of Gastric Cancer), and is divided into f-phase* progressive-gastric cancer samples. The study was approved by the Second Research Committee of Kaohsiung Rongmin General Hospital. All patients and control groups were informed. Recent studies indicate that the occurrence of intestinal type gastric cancer is a multi-step event, 1 ^(superficial gastritis) > f ^ (atr〇ph; 'gastritis), small intestine degeneration (intestinal (10) postal (four), hair dysplasia evolved into a malignant tumor, through cumulative multiple genetic changes x ^ = quality rich, structural or functional changes. Disseminated gastric cancer, 1 adhesion molecules ^ ^ i ^ li ^ l ^ (E-cadherb) > loss of catenin and annexin_7 are also involved in its canceration. w, (1) k Because the gastric epithelial cells in the stomach will cause changes in gastric juice composition during the process of gastric cancer, the gastric juice protein described here finds a new type of tumor special marker to screen for gastric malignant tumors. The gastric autologous concentration of the gastric and duodenal patients' gastric juices and the biomarkers for the discovery of new diseases. m The total protein production of gastric juice is determined by the Bradford method (21). 5Gpg per Tablet gel) is used in 2D electrophoresis $2 = protein dot by mass spectrometry analysis. - contains about 5 samples with acetone (1 to 2Wv) at about _2Gt: sinking the temple for about 2 hours, 18 200817682 The solution was centrifuged at 10,000 xg for 10 minutes at 4 ° C. The precipitate was rehydrated (9 M urea, 35 mM Tris, 42 mM DTT, 2% CHAPS, 0.66% SDS, 2% IPG buffer, trace bromophenol blue) Mix and add to a fixed pH gradient IPG strip, 11 cm, non-linear, pH 4-7 (Amersham Phamacia Biotech, Immobiline Dry-Strip, Uppsala, Sweden) for overnight overwatering at 30V. Two-dimensional electrophoresis was performed on the second-dimensional gel electrophoresis. The first-dimensional gel separation was performed using a commercially available, specialized apparatus, for example, IPGphor (Amersham Phamacia Biotech). The protein was continuously concentrated at about 200 V, about 1 Hours, about 500V, about 1 hour, about 1000V, about 1 hour. Then carry out a gradient of about 1000V to 8000V for about 30 minutes. Then continue to concentrate on 8000V for about 8 and a half hours to get a total amount of IPGphor. 70kVh. In the second dimension, the PG is balanced 50 mM tris-CL, pH 8.8, 6 M urea, 30% glycerol, 1% DDT, and bromophenol blue for about 12 minutes, followed by 50 mM tris-CL, pH 8.8, 6 M urea, 30% glycerol, 1.2% SDS , 2% iodoacetamide, and bromophenol blue for about 12 minutes. The strip was placed on a 15% gradient poly-amine gel plate (190 X 140 X 1 mm) and the gel was electrophoresed to the next day. The gel was dyed with silver nitrate. The protein in the gel was recorded as a digital image by a GS-710 Calibrated Imaging Densitometer (Bio-Rad). Gel image alignment was performed using PDQuest software (Bio-Rad). Further, prior to the extraction of the protein from the two-dimensional gel, digestion of the gel fragment by porcine trypsin (Promega, Madison, USA) is ideally performed to digest the gelatin membrane protein S#. The resulting digested and decomposed polypeptide fragment was extracted with trifluoroacetic acid and acetonitrile (ACN) and subjected to mass spectrometry to determine its mass and amino acid sequence. The uranium at mass spectrometry was purified by ZipTip C18 (Millip〇re, Bedford, USA) according to the manufacturer's instructions. 19 200817682 Example 4: Mass spectrometry is divided into a matrix-assisted laser desorption ionization time-of-flight mass spectrometer (1^^]〇1 TOF-MS) analysis, generally, with a 2,5-dihydroxy group Mixing about 1 μl of 2,5-dihydroxybenzoic acid (5〇ηηη〇ι/μΐ in 5〇% acetonitrile) and phosphonic acid (final concentration about 〇·4%) ! A sample of gastric juice precipitated from μΐ. Other substrates known to be suitable for the preparation of protein ions are also tested in the same wire. Next, about 丨μ1 of the resulting mixture was made into a MALDI unstained steel sample pan and allowed to air dry at room temperature. Modified by ABI Voyager DE_STR MALDI-T0F mass spectrometer

(Applied Biosystems,Foster City,CA,USA)之 MALDI-T0F 質 瑨儀產生該析出樣本之多肽和蛋白質的質譜態樣。該光譜儀係 運作於正離子赋並具—25 kV之加速電壓。雜質量閥設定 於500 m/z。蛋白質資料庫搜索工具“ pr〇f〇und,, (http://www.i29.85J92/profoundbinIWebp^^ 用於比較该胰蛋白酶片段的單一同位素m/z值與其在資 料庫中己知蛋白質的值。 该知·殊彳寸彳政係為其變更微管道盤(micr〇channel plate)獲得和 雷射能量測量的能力。-外部的雷射係被用於獲得嫩⑽圖 譜(spectm)。以具有質量和電荷比例(M/Z)範圍1〇〇〇至1〇,〇〇〇 之陽^子模式獲得大部份的圖譜。以約2G mj/em2至約3〇〇 =j/:m >之雷射注量和以ι〇〇次雷射發射之累積獲得一典型之 質置圖譜。正常和癌症病患的樣本係於同樣的雷射注量下施 行。 MALDI-TOT紐提供明確蛋白質特性之樣本係藉由電喷 務MS/MS做進-步研究。該胰蛋自酶消化分解之上清液係以 C18 HPLC純化和濃縮。該濃縮後的蛋白質/多肽樣本接著利 用^電噴霧(nanoflow elect卿ray)自金包覆 (gold-coated glass capillaries)喷灑。該 MS/MS 圖譜係藉由一 The麵FT-ICR質譜儀(Therm〇細酿,B臟 20 200817682 得並利用於資料庫搜尋,藉由MASC0T胺基酸相搜尋 (httP://www.matriXscience.com)於胺基酸鑑定以和 料庫做確認。 P 貝 正常者和癌症病患的典型質譜係個別於第5A圖 呈現。藉由比較正常、無疾病受測者胃液樣本 & 的異常值(以質量的方式表現)餘& 非癌,本巾,小部份質譜區__不同係可藉由 親^之,’‘、需其他額外複雜的分析。因此’關於此質量峰 ° (pea )之夕肽係被鑑定為一可用於胃癌診斷之良好生 ,。其係共有5個和胃癌相關的質量峰部,其具質量和電荷二 例(m/z)於 2187、2387、3572、2573 和 4132。於其中,多肽 2广1m肽2387 _和多肽3572 _,其峰^的量在癌A MALDI-T0F mass spectrometer (Applied Biosystems, Foster City, CA, USA) produces mass spectrometric profiles of the polypeptide and protein of the precipitated sample. The spectrometer operates on a positive ion junction with an accelerating voltage of -25 kV. The miscellaneous mass valve is set at 500 m/z. Protein library search tool "pr〇f〇und,, (http://www.i29.85J92/profoundbinIWebp^^ is used to compare the single isotope m/z value of the trypsin fragment with its known protein in the database The knowledge of the micr〇 channel plate and the ability to measure laser energy. The external laser system is used to obtain the tender (10) spectm. With a mass and charge ratio (M/Z) ranging from 1 〇〇〇 to 1 〇, the 〇〇〇Yang yang sub-mode obtains most of the spectrum. From about 2G mj/em2 to about 3〇〇=j/:m > The laser fluence and the accumulation of 〇〇 雷 laser emissions yield a typical texture map. Samples of normal and cancer patients are performed under the same laser fluence. MALDI-TOT New Zealand provides clear The sample of protein properties was further studied by electrospray MS/MS. The pancreatic egg was purified and concentrated by C18 HPLC from the enzymatic digestion. The concentrated protein/peptide sample was then used. The spray (nanoflow elect ray) is sprayed from gold-coated glass capillaries. The MS/MS map is obtained by A FT-ICR mass spectrometer (Therm〇, B dirty 20 200817682 was used in the database search, identified by amino acid by MASC0T amino acid phase search (httP://www.matriXscience.com) Confirmed with the library. The typical mass spectra of normal P and cancer patients are presented separately in Figure 5A. By comparing the abnormal values of gastric juice samples & Yu & non-cancer, this towel, a small part of the mass spectrometer __ different systems can be by the pro, '', other additional complex analysis is required. Therefore 'about this mass peak ° (pea) 夕 peptide is It is identified as a good student for the diagnosis of gastric cancer. It has 5 mass peaks associated with gastric cancer, with mass and charge in two cases (m/z) at 2187, 2387, 3572, 2573 and 4132. , peptide 2 broad 1m peptide 2387 _ and polypeptide 3572 _, the amount of peak ^ in cancer

然而,多肽2573 m/z和多肽4mm/z J 表現置增加(芩見,第6圖)。 關;^Γϋ詳細内容於第6Α·6Β圖呈現並比較。明顯地, 丄/肽2387111/2和多狀3572 m/z 3個質量 量。2徊中表現但在癌症樣本中消失或是具較低的However, the polypeptide 2573 m/z and the polypeptide 4 mm/z J showed an increase in expression (see Fig. 6). Close; ^ Γϋ Detailed content is presented and compared in Figure 6Α6Β. Obviously, 丄/peptide 2387111/2 and polymorphic 3572 m/z 3 masses. 2 表现 performance but disappeared in cancer samples or lower

V 樣本中消失㊆肽2i73m/z *多狀4132m/z在正常 收隹白a曰非吊政弱’部表現於癌症樣本之中。 析。目正常受測者和癌症病患之樣本亦進行統計分 的樣本二個來自我^、主已,分^ι〇6個來自於健康正常受測者 潰瘍症*自月項瘍病患的樣本、37個來自於十二指腸 症病*二掸i本和34個來自胃癌病患的樣本。在癌症和非癌 ^ 多於15個多肽質量峰部具重要的差異 八比孕乂貝瑨的結果呈現於第^表。 21 200817682 第一表:抑制之胃癌生物標誌、 訊號 2187 m/z 樣本 陽性 陰性 正常 84 —- 22 胃潰瘍 27 —— 11 十二指腸潰瘍 35 2 胃癌 5 29 第二表:增強之胃癌生物標誌 訊號 2573 m/z 4132 m/z — 樣本 陽性 ^ 陰性 陽性 陰性 _ 正常 8 98 6 100 _胃潰瘍 7 31 9 28 二指腸潰瘍 0 37 0 37 ___胃癌 23 11 —— 16 18 〜---- 〜 2387 m/z 3572 m/z 性 陰性 陽性 陰性 〜80 26 84 22 24 — 14 23 15 ^37 0 35 2 4 ^--- 30 8 26 如果我們計算胃癌對每個乡肽的敏感度(sensitivity)和特異性 (specificity),多肽 2187 m/z、多肽 2387 心、多肽 3572 m/z 和多 肽4132m/z,其質譜敏感度個別係為85%、88%、76%和53%。 ' 多肽 2187 m/z、多肽 2387 111/2、多肽 3572 m/z 和多肽 4132 m/z, , 其貝譜特異度個別係為80%、80%、79%和92%。 $較獲得於此的結果與目前能夠作為胃癌偵測的其他血清生 勿巧遠、,該鑑定比其他之多肽生物標誌的敏感度明顯較高。例如, 在L床上’癌胚胎抗原抗原(cea)和碳水化合抗原(CA19-9)係為胃 癌中隶常使用之血清生物標記。該血清CEA和CA19-9於胃癌偵 ,的敏感度僅有18%和29%。一近期之研究顯示,於胃癌偵測時 月液中增加之CEA和CA19-9的敏感度係為27%和17%,個別 =此外’其他近期鑑定之生物標諸’例如,血清p53抗體和基 貝金屬蛋白酶-1 (matrix metall〇proteinase-1,TIMP-1)的組織抑制 22 200817682 劑’應用於偵測胃癌時,其敏感度非常地低(15%和17%,個別 地)。因此,胃液CEA和CA19-9於胃癌診斷的實用性是非常有 限的’然而’鏗定於此的多肽生物標誌具有相當高的敏感度且於 胃癌偵測非常有用。 ,疋於此的多肽和蛋白質生物標誌的優勢為它們的高敏感度 和特異性。例如’於胃癌偵測中,胃液α-抗胰蛋白酶前驅物的敏 ^度和特異性個別為93%和83%。就我們所知,α-抗胰蛋白酶 荊驅物係為一胃液中新型的生物標誌,在其它目前可獲得的生物 標誌之中,其對於胃癌偵測具有最高的敏感度。In the V sample, the disappearance of the heptapeptide 2i73m/z * polymorphism of 4132m/z is shown in the cancer sample in the normal harvesting white a曰 non-hanging weak. Analysis. Samples of normal subjects and cancer patients were also statistically sampled. Two from my ^, the main, and ^^ were 6 samples from healthy normal subjects with ulcers* from the monthly disease. 37 samples from duodenal disease * diazepam and 34 patients from gastric cancer. There are important differences between cancer and non-cancer ^ more than 15 peptide mass peaks. The results of the eight-pregnancy 乂Beibei are presented in the table. 21 200817682 The first table: inhibition of gastric cancer biomarkers, signal 2187 m / z sample positive negative normal 84 --- 22 gastric ulcer 27 —— 11 duodenal ulcer 35 2 gastric cancer 5 29 Second table: enhanced gastric cancer biomarker signal 2573 m / z 4132 m/z — positive sample ^ negative positive negative _ normal 8 98 6 100 _ gastric ulcer 7 31 9 28 duodenal ulcer 0 37 0 37 ___ gastric cancer 23 11 —— 16 18 ~---- ~ 2387 m/ z 3572 m/z Sexual negative positive negative ~80 26 84 22 24 — 14 23 15 ^37 0 35 2 4 ^--- 30 8 26 If we calculate the sensitivity and specificity of gastric cancer for each peptide Specificity, polypeptide 2187 m/z, polypeptide 2387 heart, polypeptide 3572 m/z and polypeptide 4132 m/z, the mass spectrometry sensitivity was 85%, 88%, 76% and 53%. ' Polypeptide 2187 m/z, polypeptide 2387 111/2, polypeptide 3572 m/z and polypeptide 4132 m/z, and its shell specificity was 80%, 80%, 79% and 92%. The results obtained from this comparison with other sera currently available for detection of gastric cancer are significantly more sensitive than other peptide biomarkers. For example, on the L bed, the cancer embryo antigen antigen (cea) and the carbohydrate antigen (CA19-9) are serum biomarkers commonly used in gastric cancer. The sensitivity of serum CEA and CA19-9 in gastric cancer detection was only 18% and 29%. A recent study showed that the sensitivity of CEA and CA19-9 increased in the monthly fluid at the time of gastric cancer detection was 27% and 17%, respectively = in addition to 'other recently identified organisms labeled 'for example, serum p53 antibodies and Tissue inhibition of matrix metall〇 proteinase-1 (TIMP-1) 22 200817682 The sensitivity of the drug used in the detection of gastric cancer is very low (15% and 17%, individually). Therefore, the utility of gastric juice CEA and CA19-9 in the diagnosis of gastric cancer is very limited. However, the polypeptide biomarkers identified here have a relatively high sensitivity and are very useful for gastric cancer detection. The advantages of peptide and protein biomarkers here are their high sensitivity and specificity. For example, in the detection of gastric cancer, the sensitivity and specificity of the gastric juice α-antitrypsin precursor were 93% and 83%, respectively. As far as we know, α-antitrypsin is a novel biomarker in gastric juice, and among other currently available biomarkers, it has the highest sensitivity for gastric cancer detection.

實施例5 :統計公杜 利^〃SPSS程式(第ιο ί版,Q^gojuinois, USA)施行統計 分才二第ίο圖呈現健康受測者、胃潰瘍(GU}、十二指腸潰瘍(Du) 和胃癌(GC)病患的人口特徵。胃癌病患明顯較健康受測者年長 (67j年51·4^,ρ <0·001)。此外,該胃癌病患族群與健康受 測者,較具一較高的男比女之比例(p=〇 〇54)。在鑑定的族群間, 胃癌家族歷史和飲酒歷史無明顯的不同。 然而,月/貝瘍和十二指腸潰瘍病患的吸煙比例明顯較健康 *嶋,個別地)。再者,十二指腸潰瘍病患的 感乐率亦明顯較健康受測者為高((ρ=〇 〇34)。 代。第在1康i測者和胃十二指腸疾病病患胃液樣本的特 t #在二,貝瘍、十二指腸潰瘍(Du)和胃癌(gc)族群間胃液 胃酸pH和全部蛋白質濃度的相異係藉由單因子變數^ (one_wayANOVAtest)而決定。 祈 月液中多肽含量也是-項重要指標,在 病=顯較健康受測者高(44%和55% vs、27%; p <〇=貝= t 。㈣,在十二指輯翻患轉毅測者m量並 ,顯的不同。胃液的PH值於健康受 值於胃潰瘍和胃癌絲明顯較健康受測者高(p ,01 % 23 200817682 财倾十二指腸絲料具魏低的胃液 質濃度個別V〇:8、ΐί 〇 =指2腸潰瘍和胃癌病患的全部蛋白 群中胃癌病患的全部蛋白質濃 °明顯地’在4個族 白質濃度日_職受潰瘍病患的全部蛋 指腸潰瘍病患具有一較低的全部蛋白相較和十二 標準差加2,質濃度; 和胃癌病患的22%、36%、8%和十—Μ潰瘍病患 在m,具有或不具有耶兹校正 contnnnty)和費雪精確檢定(Fi^ _ (i 輸t應用於分析人類胃部中影響全部蛋白 估雜全=2 Ϊ ^斤迴歸(1〇giStic regression)白勺變異分析以ί 白錄度的獨立因子為高(高於〇·5吨編之全部蛋 J ^又)或為低(低於〇.5mg/ml之全部蛋白質濃度)。這些因子 係已括至少11個臨床因子、細菌因子、胃液因子和其他。例如, 研究於士的因子係包含年齡(低於或高於6〇歲)、性別(男或女)、 胃癌的豕族歷史(有或無)、抽煙歷史(少於或多於1包/週)、飲酒 歷史(少於㈠或多於(+) 8〇g/天)、細菌感染(丑砂/〇rz•感染情形的表 現f不表現)、胃液特徵(少於或高於5 ml胃液;胃液的酸度低於 或南於約pH 3.5)、胃潰瘍(有或沒有)、十二指腸潰瘍(有或沒有)、 胃癌(有或沒有)的表現或不表現。 在一方面’胃液中影響蛋白質濃度之多個因子被同時地評估。 例如’ 11個臨床因子、細菌因子和胃液因子係被比較並發現獨立 參數。 第12圖展現影響人類胃部全部蛋白質濃度因子的單變數分析 結果。在/>< 0.05時相異度係被考慮為有意義。該結果顯示,至 24 200817682 ΙΙΐίΛ的因子明顯地與高蛋白質濃度相關(例如,高於約ο.5 +二’包括老化(P =aG()1)、胃癌家族歷史(P =G.054)、 蛋白躲_靠行—錢齡析,以尋找全部 全部蛋的任何’°第13圖呈現人類胃部影響 .1-26-8.2Τ);,, 95% ^ fBl(CI)): -素人自們也·Γί,騰蛋白酶為一胃液中活躍的蛋白質分解酵 pH>6日^不可读起^里ί的功效,於PH 4-6不活化但是穩定,於 化分解的㈣。Γ t蛋自制組㈣受於酸性胃酸胰蛋白酶消 f低酸度胃液之高蛋白質濃度係可理解。 少,前列腺素ϋίί,胃^生理的改變(例如,黏膜血液流量的減 ίί ΪΓ ί胃潰瘍和胃癌的發生的主要危險因子,^ 白質iiiitt物)的高發生率。但是有關於在胃液中高蛋 :研究來· 型係根據其神經網路、資气新式—般神經網路模 面於單一網路結⑽=:==)介 25 200817682 群集(clustering)、分類、功能近似值(functi〇n appr〇ximati〇n)和簡 易評鑑,Reference: 1 Chen,Υ· Υ· (2005)· Neural networks,fuzzy logic and statistical inference. Neural Networks((2006) to appear); 2. Chen? Y. Y. and Chen, J. J. (2004). Neural networks and belieflogic, Proceedings of the Fourth International Conference on Hybrid Intelligent Systems (HIS904)} IEEE, 460-461; 3. Chen, Y. Y. (2002). Plausible neural networks. Advance in Neural Networks World. EdExample 5: Statistics of the public Douli ^ 〃 SPSS program (the first ιο ί version, Q ^ gojuinois, USA) statistic scores two ίο map showing healthy subjects, gastric ulcer (GU}, duodenal ulcer (Du) and stomach cancer (GC) The demographic characteristics of patients. Patients with gastric cancer were significantly older than those who were healthy (67.51^4^, ρ <0·001). In addition, the gastric cancer patients and healthy subjects were compared. There is a higher ratio of male to female (p=〇〇54). There is no significant difference in family history of gastric cancer and drinking history among the identified ethnic groups. However, the proportion of smoking in patients with monthly/beat ulcer and duodenal ulcer is obvious. More healthy *嶋, individually). Furthermore, the sensory rate of patients with duodenal ulcer is also significantly higher than that of healthy subjects ((ρ=〇〇34). Generation. The first t-test of gastric juice samples of patients with stomach and duodenal diseases In the second, the difference between gastric acid pH and total protein concentration in the gastric ulcer, duodenal ulcer (Du) and gastric cancer (gc) group is determined by the single factor variable ^ (one_wayANOVAtest). The polypeptide content in the moon liquid is also - Important indicators, in the disease = significantly higher than the healthy subjects (44% and 55% vs, 27%; p < 〇 = Bay = t. (4), in the twelfth of the series turned over the tester, and Significantly different. The pH value of gastric juice is higher in health than in gastric ulcer and gastric cancer. (P, 01% 23 200817682 The duodenal silk has a low gastric gastric concentration. V:8, ΐί 〇= refers to the total protein concentration of gastric cancer patients in all the protein groups of 2 intestinal ulcers and gastric cancer patients. It is clearly 'in all the patients with egg-gut ulcers in 4 groups of white matter concentration days. Low total protein compared with 12 standard deviation plus 2, quality concentration; and 22%, 36%, 8% and ten-Μ of gastric cancer patients Patients with ulcer disease at m, with or without Yates correction contnnnty) and Fisher's exact test (Fi^ _ (i lost t used in the analysis of human stomach affects all protein estimates total = 2 Ϊ ^ kg regression (1〇 The giStic regression analysis is based on the independent factor of ί whiteness (higher than 〇·5 tons of all eggs J ^) or low (less than 〇.5mg/ml of total protein concentration). The factor system has included at least 11 clinical factors, bacterial factors, gastric juice factors, and others. For example, the factor of the study includes age (below or higher than 6 years old), gender (male or female), and gastric cancer. History (with or without), smoking history (less or more than 1 pack/week), drinking history (less than (one) or more (+) 8〇g/day), bacterial infection (ugly sand/〇rz• infection) The performance of the situation does not show), gastric fluid characteristics (less than or higher than 5 ml of gastric juice; acidity of gastric juice is lower than or about pH 3.5), gastric ulcer (with or without), duodenal ulcer (with or without), gastric cancer ( Performance with or without performance. On the one hand, multiple factors affecting protein concentration in gastric juice are Time assessment. For example, '11 clinical factors, bacterial factors and gastric juice factor are compared and found independent parameters. Figure 12 shows the results of single variable analysis affecting the total protein concentration factor in human stomach. At />< 0.05 The degree of dissimilarity is considered to be meaningful. The results show that the factors up to 24 200817682 ΙΙΐίΛ are clearly associated with high protein concentrations (eg, above about ο. 5 + two' including aging (P = aG() 1), gastric cancer Family history (P = G.054), protein hiding _ relying on the line - money age analysis, in search of all the eggs of any '° figure 13 shows human stomach effects. 1-26-8.2 Τ);,, 95% ^ fBl(CI)): - Amateurs also Γί, TG is an active protein decomposing pH in a gastric juice. The effect of 6 liters is not readable. It is not activated but stable at pH 4-6. (4). Γ t egg homemade group (4) is affected by acid gastric acid trypsin elimination f low acidity gastric juice high protein concentration is understandable. Less, prostaglandin ϋίί, gastric ^ physiological changes (for example, mucosal blood flow is reduced by ί ί ί gastric ulcer and the main risk factors for the occurrence of gastric cancer, ^ white matter iiiitt) high incidence. But there is a high egg in the gastric juice: research comes from the type according to its neural network, the new type of neural network - the neural network surface is in a single network node (10) =:==) 25 200817682 clustering, classification, Functional approximation (functi〇n appr〇ximati〇n) and easy evaluation, Reference: 1 Chen, Υ· Υ · (2005) · Neural networks, fuzzy logic and statistical inference. Neural Networks ((2006) to appear); 2 Chen? YY and Chen, JJ (2004). Neural networks and belieflogic, Proceedings of the Fourth International Conference on Hybrid Intelligent Systems (HIS904)} IEEE, 460-461; 3. Chen, YY (2002). Plausible neural networks. Advance in Neural Networks World. Ed

Grmela,A· andMastorakis,Ν· E· WSEAS Press, 180_185·)。我們的Grmela, A· and Mastorakis, Ν· E· WSEAS Press, 180_185·). our

結果指出在正常和潰瘍病患間的區別非常清晰且結合胃液樣本的 質譜的PNN程式可分辨出癌症樣本和正常樣本。 貫施例7·應用蛋白質純化層;j:主色層分析以鑑定候撰分子 因為在人體中有許多蛋白質被製造質譜儀相對 低貝i解析度的質譜並不精確到足以鋥定這些質量峰部對應的蛋 白質或多肽。許多蛋白質具有可合併為一個質量峰部的分子量。 一個二步驟的方法係被應用於鑑定這些生物標諸。 首先,HPLC被利用於先前分離這些析出的樣本。一典型的結 ^於第7圖呈現,其係介紹一鑑定之多肽生物標誌的HpLe圖 ^^自HPLC的每個峰部,我們進一步施行質量圖 譜=析,j鑑定哪個HPLC區間包含感興趣的質量峰部的物質。 ^結果於第8A_8C圖呈現,其係介紹在111&gt;1^層柱色層純化之後, 月本的三個區份的質譜於質量範圍500m/z至5000m/z。 列譜儀純化候潠生物標铁分子和鑑定胺基酸戽 I的分子(target molecules)係藉由蛋白質色層分析,例如,C18 ’純1匕和濃縮以準備進行進一步的胺基酸序列鑑定。該 9 圖譜接著以一 ABI 4700質譜儀獲得。一典型的圖譜如第 庠現’其顯示MS/MS分析於一實驗的多肽(2187m/z)胺基酸 和/式’I定的結果。以mscot胺基酸定序搜尋引擎之搜索,多肽 次蛋白質的序列可被鑑定。除了多肽2187m/Z,多肽2387m/Z、 26 200817682 多肽3572m/z、多肽2573m/z以及, 根據本發明之-鐵乡似體* Z的糊亦被鑑定。 獲得胃液並續行蛋白質體分析收集方式 部份胃癌潛在病患和已存在病患,’其能於^ yt5 CEA^CA^ 試驗,描述於此的診斷/篩選方法和田 值的血/月 較高之敏感性和特異性 去和“生物標誌、於胃癌偵測提供The results indicate that the difference between normal and ulcerated patients is very clear and the PNN procedure for mass spectrometry combined with gastric fluid samples can distinguish between cancer samples and normal samples. Example 7: Applying a Protein Purification Layer; j: Primary color layer analysis to identify a candidate molecule Because a mass spectrometer with many proteins in the human body is manufactured with a relatively low mass spectrometer mass spectrometer is not accurate enough to determine these mass peaks A corresponding protein or polypeptide. Many proteins have molecular weights that can be combined into one mass peak. A two-step method was applied to identify these biological targets. First, HPLC was utilized to previously separate these precipitated samples. A typical knot is presented in Figure 7, which introduces an HpLe map of a identified peptide biomarker from each peak of HPLC. We further perform a mass map = analysis, which identifies which HPLC interval contains the interest. The mass of the peak material. The results are presented in Fig. 8A_8C, which shows that the mass spectrum of the three fractions of the moon is in the mass range of 500 m/z to 5000 m/z after the purification of the layer of the column layer. The spectrometer purifies the candidate biomarker iron molecules and identifies the target molecules of the amino acid hydrazone I by protein chromatography analysis, for example, C18 'pure 1 匕 and concentration to prepare for further amino acid sequence identification. . This 9 map was then obtained on an ABI 4700 mass spectrometer. A typical map is shown in Figure </ RTI> which shows the results of MS/MS analysis of an experimental polypeptide (2187 m/z) amino acid and /. The sequence of the polypeptide sub-protein can be identified by a search of the mscot amino acid sequencing search engine. In addition to the polypeptide 2187m/Z, the polypeptide 2387m/Z, 26 200817682 polypeptide 3572m/z, the polypeptide 2573m/z, and the paste of the iron-like body *Z according to the present invention were also identified. Obtaining gastric juice and continuing to analyze the proteomic analysis of some patients with gastric cancer and existing patients, 'can be used in ^ yt5 CEA ^ CA ^ test, describe the diagnosis / screening method and field value of blood / month higher Sensitivity and specificity to go with "biomarkers, for gastric cancer detection

C ±胃液的3凝膠電泳施3 患' 33位十二指腸潰瘍病患和29位位月/貝瘍病 :質電泳圖像的結果分類成為3種態樣:盆中 石4條帶態樣、特殊條帶態樣和非特殊條帶態樣。,-係w 土 本二建康ΐϊί各ΐ胃與十二指腸潰癌病患胃液樣 條帶能^田:Η =基礎條帶紐、特殊條帶態樣和非特殊 健康受測 c 病患r胃癌病患樣本的經計算後頻率個別為 係; 該/果1i圖介紹=_泳縣條帶態樣與癌症演轴_結果。 田第16圖係於胃液樣本中的二維電泳態樣,呈火 K=度__。小體的腺㈣縮和胃部低酸=特= 恕幽鳄紐高度相_者皆〜觀):基f夺帶、 寸殊“和非特殊條帶的頻率於低酸度胃液二維電泳圖中個別為 27 200817682 0〇/〇、93%和 7%。 在9位受過胃黏膜組織檢查的健康受 一 者不具胃部萎縮,造成胃液二維凝與 ^康,測 膠電泳研究中呈現一非特殊條帶態樣。文細)之枚本於二維凝 第17圖為一例示二維凝膠電泳 i 要條帶在酸性Ρΐ (4.ϋ·5·α)可被觀察到:^ 條42 kDa之分子量係被定名為 由、而=C 3 gastric electrophoresis 3 gel electrophoresis 3 suffering from '33 duodenal ulcer patients and 29th month / shell disease: the results of the mass spectrometry image classification into three kinds of: the basin stone 4 strips, special Striped and non-special strips. ,- Department w Tuben two Jiankang ΐ ΐ ΐ stomach and duodenal ulcer patients with gastric juice sample band can ^ field: Η = basic strips, special strips and non-special health test c The calculated frequency of the patient sample is individual; the 1i map introduces the _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tian No. 16 is a two-dimensional electrophoresis pattern in a gastric juice sample, showing a fire K=degree __. Small body gland (four) contraction and stomach low acid = special = 幽 crocodile crocodile new height phase _ all are ~ view): base f take band, inch "and non-special band frequency in low acidity gastric juice two-dimensional electropherogram The individual was 27 200817682 0〇/〇, 93% and 7%. The health of one of the 9 patients who had undergone gastric mucosal examination did not have atrophy of the stomach, resulting in two-dimensional coagulation of gastric juice and Kang, and the gel electrophoresis study showed a The non-special strip pattern. The text of the text is in the two-dimensional condensation. Figure 17 shows an example of two-dimensional gel electrophoresis. The strip is in acid Ρΐ (4.ϋ·5·α) can be observed: ^ The molecular weight of the strip 42 kDa is named as, and =

-TOF和MS/MS質譜儀分析梦定或睡Ια A 7接者糟由MALDI 退=TOF *析中被齡為2個明顯的多肽峰部於 於 mz 538。來自質_兩個多肽峰部紐鑑定為 ^ 列(QJFTVFDR)的胰蛋白酶A前驅物。U相同域酸序 第18圖為-例示二維凝膠電泳圖像,其係展示— ,樣。鏗讀基礎條帶態樣的終自 不二 名為則且可顯著地偵測的到。該來自 恶樣的條帶,因此對應於胰蛋白酶A前驅物和』ί ^ίίΐΪΪΐ條帶餘觀察的到。在非特殊性二維凝膠電泳條 酶^制^ k貝墨點】的分布是相當多樣的。部份淋巴球彈性蛋白 ΪΓ inhibitorXM, 43kDa; pi, 5.90) . I」^ 物 gldn_1 师⑽·)(攸 114kDa; P1,4.90)、橋 ϋ 叩驗)(錢332kDa;pI,6.44)和1g K鍊C部位(胁 之墨定⑻的片段係由分散於二維凝膠呈現麵殊條帶態樣 28 200817682 電泳圖像的基礎條帶態樣係包含二個由胰蛋白二 所組成之主要條帶。此基礎條帶態樣的 在餘別驅物 (,和十二指腸潰瘍病患_之中。相=者 電泳圖像主要係為特咖条帶態樣(93%)。因 ^患中該 圖像的特殊條帶態樣和非特殊條帶態樣高度地變動ϋ;的電泳 3二。ΐ;她系指出,胃液分析中至少_的胃癌病患且42 偵測胃癌出現非常敏銳之方法。 物係為—在病患中 Γ 在此主現,月液中“—抗胰蛋白酶前 縮和胃部的低酸度高度相關。其可能是,-多餘的Λ體委 流入/部3,、、可立在低酸度胃液中避免被快ίί白質水的^貝蕩的傷口 ^測者胃部全部不具腺體萎縮。相反地 松的唯-健康受測者具有明顯 寶室寸殊=:悲 腸變性生長。 具有胃癌的潛在條件,例如萎縮和小 利用前述之過程,鏗定胃癌受永 多肽2187 m/z,1且有相對’包含一多肽生物標諸、, FLKKHNLNPARKYFpqw , Μ ^ 蛋白酶原多肽片#日# m/Z,亦具有相對應於胰 flkkhnlnparkyfp^^a且^疋2個胺基酸之序列 (chiefcell)所分泌。胃邻产化屛/夷蛋白酶原係由胃部的主細胞 數目減少i胰蛋白酶胃部萎,過程,其導致主細胞 蛋白酶原片段受抑制量之鐘“胃=化胃液中2個胰 另一個鑑定而得的胃癌受抑制多月太山為多月^其包含具 29 200817682 有^ 列】TKKTEDRFVPSSSKSEGKKSREQPSVLSRY 之亮氨酸拉 鏈a白,區域(leucme zipper protein domain)。亮氨酸拉鏈蛋白質 區域經系表現於腫瘤抑制蛋白質(tum〇r suppress〇r坪说咖)中。某些 腫瘤抑制蛋白質的表現在人類胃癌細胞株被發現受到抑制。 酸拉鏈蛋白質的抑制亦曾在胰臟癌、口腔鱗狀上皮細胞癌(⑽^ squamous cell carcinoma)和膀胱癌(Wadder cancer)被報告。某些亮 氨酉文拉鏈蛋白質的表現誘發細胞凋亡(叩叩t〇sis)並減少在某些人 類細麟的細胞絲度。該亮氨雜鏈蛋自f乡肽#段,多狀3一Μ Γ ==應於-潛能,瘤抑制蛋白f,其表在胃和胰臟癌細胞株 =生丨i此’'亥梵氨酸拉鏈多肽片段(3572m/z)在胃癌病患胃液 的鑑定係暗指在胃癌細胞或萎縮胃部黏膜中相對應亮 氣酉文拉鍵蛋白質的抑制。 自質譜分析的胺基酸鑑定結果亦鑑定胃癌向上調控 t^ulated)的多肽。一多肽,多肽2573 m/z,鑑 之自蛋自錄此。因為白 (Lui bl / 且在胃癌裡自形成潰瘍_瘤中隱藏出血 的過尸二Γΐ二吊見現象,所以可能是在胃癌發生和腫瘤出血 ’來液的白蛋白流人胃液。因此,該白蛋白多肽片 ί ^1 1 ^^ t:致。再者,胃液中白蛋白的存在可做為-警示, 必肩更仔細確遇月癌存在之可能性。 笋定在田 膠電泳後,質譜分析鑑定之胺基酸序列結果 11向上调控的蛋白質。一蛋白質,多肽4132m/z, A 白酶前驅物,岸 ,,% 疋口為α1—抗胰蛋白酶在血液中含量报高,並、盘切炎 ,^ 胰蛋白酶可在胃癌發生過程腫瘤出血時血田、、α几 因為鑑定於此的多肽和蛋白質,在w 入月液。 特異性非常的高,高於任^中^胃癌的敏感度和 曰月j j獲侍的胃癌生物標誌,在胃液 30 200817682 類蛋白質和多肽片段的出現在胃痒病•中是 早株抗體係可發展於胃癌篩檢或診斷。a和夕肽片段的 , 施行,該鑑定於此之多肽片岸γ 素性的消化分解被 .症病n常相被觀察啊微結果在癌 質)财為良好的生物標諸。*殊夕肽片&amp;(而非該全長蛋白 胃癌。因此,正異指出不同來源的癌症但非 little ^目/、自於月部。甘亦#匕出+ 广自 Θ 質和;月太片段‘ 其他可能的考虞^、,二疋自於其他器官的可能性較小。 -能存在於胃炎和胃^的‘ 抑制f白蛋白的向上調控亦 性生長兩者皆為癌化前:情§形,:呈萎縮性胃勤爾 同f發生之偵測則提d炎和胃癌間2別白ff田1特殊多肽 多肽之相同表現’其仍為-確定胃癌或癌:ίίίίΞ 胃:本仏巧™患 病患的胃液蛋白質濃度則較健康受測 31 200817682 在-方面,—彳目^^^^1度_立因子。 係可做為—新式 ^ H 祕胃液並續行蛋白質體分析的方法 與十二指腸疾2病患^=ϊί'3ί °在另—方面,各式胃 式胃與十二指腸二it:液找主要蛋白質成份明顯在各 本發明之具體實施例係提供第一 f病中胃液蛋白質濃度岐異、。在胃液/,胃/田二指腸 生物標諸被鑑定 特殊條帶態樣。在胃液中至少$個新 胃液中蛋白質、! 貝❼析。4發現高度指出,測量 伤炎冰〜、’辰又亚、、、口 ^蛋白質體分析以分析胃液中蛋白皙έ日士 檢ί式胃與十二指腸疾病出現的新式 且體、^:^根據树0狀具體實補,本發批其他或進1步 /、,貝轭例可在不偏離本發明範 = / 下申請專利範圍所界定。因卜饭W且其靶圍由以 【圖式簡單說明】 ,其係根據本發明之一個或多 第1圖為一例示方法之圖示說明 個具體實施例。 多紐之圖賴明,其絲齡糾之一個或 第3圖為為利用不同磁性珠球,例如:C8或C18,收集胃液樣 t以行質譜分析之例示圖示說明,其係根據本發明之具體實 例 第4圖介紹以微量離心管收集之胃液樣本並準備進行質譜分 析,其係根據本發明之一個具體實施例。 、°曰刀 弟5Α圖為一收集自正常、未受疾病感染受測者之胃液樣本的 32 200817682 例^1_貝邊,其係根據本發明之一個具體實施例。 據病患之胃液樣本的例示質譜,其係根 =6B:示收集自癌症受測者胃液樣本之質譜之例示 弟7圖為一鑑定之多肽生物標誌的Ηριχ圖表 ―、 明’其係根據本發明之一個具體實施例。 ’、回不祝 r pf —胃錄梭由HPLG層柱色層分析純倾,於質量 Γ =圍』0 m/z至_ m/z 一區份之質譜,胃液樣本一區= 。曰,,、係根據本發明之一個具體實施例。 、 rpf:圖為一胃液樣本經由HPLC層柱色層分析純化後,於質量 巧其係根據本發明之一個具體實施例。 r円第^圖為一胃液樣本經由HPLC層柱色層分析純化後,於質量 ϋ〇0 至5〇〇〇 m/z 一區份之質譜,胃液樣本之再另一區份 之貝譜,其係根據本發明之一個具體實施例。 9/圖^胺基酸序列決定之例示圖示介紹,其呈現例示多肽 笛2 q/MS分析之結果,根據本發明之—個具體實施例。 和田W二、壬現健康受測者與患有胃潰瘍(剛、十二指腸潰瘍(DU) 和月癌(GC)之人口統特徵。 ,1圖表列健康受測者和各式胃十二指腸疾病,包括胃潰瘍 々1、十二指腸潰瘍(DU)和胃癌(GC)的胃液特徵。 第12®呈現與胃液中高蛋白質濃度相關之u個臨床、細菌和 月液因子的單變數分析。 第13圖為在單變數分析後,更進一步羅吉斯迴歸分析的結果, 其顯不影響胃部蛋白質濃度之獨立因子。 第14圖為各式胃十二指腸疾病,包括胃潰·、十二指腸 &gt;貝瘍(DU)和胃癌(GC),胃液二維電泳態樣的統計分析。 33 200817682 第15圖為一癌症演進對於α-抗胰蛋白酶前驅物分析的結果, 其確認α -抗胰蛋白酶前驅物特殊地和進階癌症(90%)和早期癌症 相關(100%)。 第16圖為在胃液的二維凝膠電泳態樣中呈現萎縮性胃炎和胃 部低酸度之關連性。 第17圖介紹二維凝膠電泳圖像的例示基礎條帶態樣,其係根 據本發明之一個具體實施例。 第18圖介紹二維凝膠電泳圖像的例示特殊條帶態樣,其係根 據本發明之一個具體實施例。 第19圖介紹二維凝膠電泳圖像的例示非特殊條帶態樣,其係 根據本發明之一個具體實施例。 【主要元件符號說明】 (無) 34-TOF and MS/MS mass spectrometry analysis of the dream or sleep Ια A 7 stalks by MALDI regress = TOF * in the analysis of the two apparent polypeptide peaks at mz 538. The trypsin A precursor from the _ two peptide peaks was identified as the ^ column (QJFTVFDR). U Same Domain Acid Sequence Figure 18 is an illustration of a two-dimensional gel electrophoresis image showing the same. The final interpretation of the basic stripe pattern is notable and can be detected significantly. The band from the bad sample, therefore, corresponds to the observation of the trypsin A precursor and the ίίίΐΪΪΐ strip. In the non-specific two-dimensional gel electrophoresis strips, the distribution of the enzymes is very diverse. Partial lymphoid elastin inhibitorXM, 43kDa; pi, 5.90) . I"^ gldn_1 division (10)·) (攸114kDa; P1, 4.90), bridge 叩 test) (money 332kDa; pI, 6.44) and 1g K The fragment of the chain C (the mitochondrial (8) fragment is composed of two layers of the gel. The basic strip pattern of the electrophoresis image contains two main lines composed of trypsin II. This basic strip pattern is in the residual drive (and duodenal ulcer disease _. Phase = the electrophoresis image is mainly the special coffee strip pattern (93%). The special stripe pattern of the image and the non-special stripe pattern are highly variable; the electrophoresis 3 ΐ; she points out that at least _ of the gastric cancer patients in the gastric juice analysis and 42 methods for detecting gastric cancer are very sensitive The system is - in the patient's sputum, in the main liquid, "the anti-trypsin anterior contraction and the low acidity of the stomach are highly correlated. It may be, - the excess corpus callosal inflow / part 3,,, Can stand in low acidity gastric juice to avoid being wounded by ίί white water. The stomach of the tester does not have glandular atrophy. - Healthy subjects have obvious treasure compartment density =: septic degeneration. Potential conditions for gastric cancer, such as atrophy and small use of the aforementioned process, determine the gastric cancer with a permanent polypeptide 2187 m / z, 1 and have a relative 'contains A polypeptide biomarker, FLKKHNLNPARKYFpqw, Μ ^ proprotein propeptide #日# m/Z, also has a corresponding secretion from the pancreatic flkkhnlnparkyfp^^a and ^2 amino acid sequence (chiefcell). The production of sputum sputum/protease is reduced by the number of primary cells in the stomach, i trypsin, stomach wilting, the process, which leads to the inhibition of the pro-protein proteasome fragment of the main cell. The resulting gastric cancer is inhibited for many months in Taishan for many months. It contains a leucine zipper protein domain with a leucine zipper protein domain. The leucine zipper protein region is expressed in the leucine zipper protein domain. Tumor suppressor protein (tum〇r suppress〇rping said coffee). The expression of certain tumor suppressor proteins was found to be inhibited in human gastric cancer cell lines. The inhibition of acid zipper proteins was also observed in pancreatic cancer and mouth. Squamous cell carcinoma ((10)^ squamous cell carcinoma) and bladder cancer (Wadder cancer) have been reported. The expression of certain leucine zipper proteins induces apoptosis (叩叩t〇sis) and decreases in some human fines. The cell fraction of Lin. The leuco-chain egg from the f-peptide # segment, polymorphous 3 Μ Γ == should be - potential, tumor suppressor protein f, its surface in the stomach and pancreatic cancer cell line = oyster The identification of gastric juice in gastric cancer patients by the ''Hayalan zipper polypeptide fragment (3572m/z) implies that the corresponding spleen scorpion protein is inhibited in gastric cancer cells or atrophic gastric mucosa. The amino acid identification results from mass spectrometry also identified polypeptides whose gastric cancer was up-regulated. A polypeptide, peptide 2573 m / z, from the egg self-recorded. Because white (Lui bl / and self-formed ulcers in the stomach cancer _ tumor hidden in the bleeding of the corpse two cockroaches see the phenomenon, it may be in the gastric cancer and tumor bleeding 'liquid comes into the human gastric juice. So, the Albumin peptide ί ^1 1 ^^ t:zhi. Furthermore, the presence of albumin in gastric juice can be used as a warning, and the possibility of the presence of lunar cancer is more carefully observed. Mass spectrometric analysis of the amino acid sequence results in 11 up-regulated proteins. One protein, peptide 4132m/z, A white enzyme precursor, shore, % 疋 mouth is α1 - antitrypsin is reported in the blood, and Paniculitis, ^ trypsin can be used in the process of gastric cancer, tumor blood hemorrhage, a few because of the identification of the polypeptide and protein, in the w into the moon. The specificity is very high, higher than any ^ ^ ^ gastric cancer Sensitivity and the biomarker of gastric cancer in the stomach, in the gastric juice 30 200817682 The emergence of protein and peptide fragments in the scrapie • The early strain resistance system can be developed for screening or diagnosis of gastric cancer. , the application, the identification of the polypeptide on the shore γ The digestive decomposition of the prime is observed by the disease, and the result is a good biomarker. *Shuyi peptide tablets &amp; (not the full-length protein gastric cancer. Therefore, the difference between the different sources of cancer pointed out but not little ^ M /, from the Ministry of the Ministry. Gan also #匕出+广自Θ质和; Fragments 'Other possible tests ^,, and two are less likely to be from other organs. - Can exist in gastritis and stomach. 'Inhibition of f-albumin's upward regulation and growth are both pre-cancerous: § § shape,: atrophic stomach qier with the detection of f occurs to mention the same performance of the phfield 1 special polypeptide peptide between the inflammatory and gastric cancers. 'It is still - to determine gastric cancer or cancer: ίίίίΞ stomach: this The protein concentration of gastric juice in patients with 仏巧TM is healthier than the test 31 200817682 In terms of -, 彳目^^^^1度_立因子. Can be used as a new type of H secret gastric juice and continued protein body analysis The method and the duodenal disease 2 patients ^=ϊί'3ί ° in another aspect, the various gastric stomach and duodenum di: liquid to find the main protein components are clearly provided in the first f disease of each embodiment of the present invention The concentration of protein in the gastric juice is very different. In the gastric juice /, the stomach / field digestive biomarkers are identified as special strip states. In the gastric juice, at least $ of the new gastric juice protein, ! Becky analysis. 4 found highly pointed out, measuring the inflammatory ice ~, 'Chen Ya,,, mouth ^ protein body analysis to analyze the gastric juice in the protein Check out the new type of stomach and duodenal diseases, and ^: ^ according to the tree 0 shape specific compensation, this batch of other or further 1 /,, yoke example can apply for patent without deviating from the invention = / The scope of the invention is defined by the illustration of a simple method according to one or more of the first embodiment of the present invention. Lai Ming, one of the silk age corrections or Fig. 3 is an illustration of the collection of gastric juice samples t by mass spectrometry using different magnetic beads, such as C8 or C18, according to a specific example of the present invention. 4 is a view showing a sample of gastric juice collected by a microcentrifuge tube and preparing for mass spectrometry according to a specific embodiment of the present invention. The image of the gastric juice collected from a normal, unaffected subject is a gastric juice. Sample of 32 200817682 cases ^1_ bead, According to a specific embodiment of the present invention, according to an exemplary mass spectrum of a gastric juice sample of a patient, the root is 6B: an example of a mass spectrum of a gastric juice sample collected from a cancer subject, and the figure is an identified polypeptide biomarker. Η χ χ χ χ , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mass spectrometry of m/z, a region of gastric juice sample = 曰,,, according to a specific embodiment of the present invention. rpf: The figure is a sample of gastric juice purified by HPLC layer chromatography, after mass purification It is in accordance with a particular embodiment of the invention. r円第图图 is a mass spectrum of a gastric juice sample purified by HPLC layer chromatography, and then subjected to a mass spectrum of ϋ〇0 to 5〇〇〇m/z, and another fraction of the gastric juice sample, It is in accordance with a particular embodiment of the invention. 9/Fig. Illustrative illustration of amino acid sequence determination, which presents the results of a polypeptide flute 2 q/MS analysis, in accordance with a particular embodiment of the present invention. Wada W., a healthy tester and a population of stomach ulcers (duodenal, duodenal ulcer (DU) and lunar cancer (GC). 1 chart for healthy subjects and various gastroduodenal diseases, including gastric ulcers Gastric fluid characteristics of sputum 1, duodenal ulcer (DU) and gastric cancer (GC). Section 12® presents a single variable analysis of u clinical, bacterial and lunar fluid factors associated with high protein concentrations in gastric juice. Figure 13 shows the analysis of single variables. After that, the results of the logistic regression analysis further showed that it did not affect the independent factors of gastric protein concentration. Figure 14 shows various gastroduodenal diseases, including gastric ulcer, duodenum, TB, and gastric cancer ( GC), Statistical analysis of two-dimensional electrophoretic patterns of gastric juice. 33 200817682 Figure 15 shows the results of a cancer evolution analysis of α-antitrypsin precursors, which confirmed α-antitrypsin precursors specifically and advanced cancers ( 90%) is associated with early cancer (100%). Figure 16 shows the association between atrophic gastritis and low acidity in the stomach in a two-dimensional gel electrophoresis pattern of gastric juice. Figure 17 shows a two-dimensional gel electrophoresis pattern. Exemplary base strip This is a specific embodiment of the present invention. Figure 18 is a diagram showing an exemplary special strip pattern of a two-dimensional gel electrophoresis image, which is based on a specific embodiment of the present invention. An exemplary non-special strip pattern of a gel electrophoresis image is according to a specific embodiment of the present invention. [Description of main component symbols] (none) 34

Claims (1)

200817682 十、申請專利範圍: 1. 一種鑑定胃與十二指腸疾病生物標誌的方法,其包含: 自一人類受測者收集一個或多個胃液樣本; 於該一個或多個胃液樣本施行一質譜分析以產生一個 或多個質譜; 比較該一個或多個質譜和一基礎線質量值之質譜;並 鑑定一個或多分子之異常質量值,該一個或多個分子 係為該胃或十二指腸疾病之生物標誌。 2. 如申請專利範圍第1項之方法,其中該胃與十二指腸疾 病係選自於一包含胃癌、胃潰瘍、十二指腸潰瘍及其組 合之族群。 3. 如申請專利範圍第1項之方法,其中基礎線質量值之質 譜係得自一正常、未受疾病感染之受測者胃液樣本。 4. 如申請專利範圍第1項之方法,其中該一個或多個胃液 樣本收集自一試驗,其係選自由内視鏡分析、一具有吸 收線繩之膠囊及其組合所組成之族群。 5 ·如申請專利範圍第1項之方法,進一步包含由該一個或 多個胃液樣本分離蛋白質,透過一蛋白質純化分析,其 係選自於一包含磁性奈米粒子蛋白質純化試驗、鑽石奈 米粒子蛋白質純化試驗、HPLC蛋白質純化色層分析試 驗、離子交換蛋白質純化色層分析試驗、二維凝膠、西 方墨點、毛細管電泳及其組合之之族群。 6.如申請專利範圍第1項之方法,其中質譜分析選自一由 MALDI-TOF質譜分析、電喷霧質譜分析、脫附電喷霧 35 200817682 二譜分析和雷㈣發原聲脫㈣譜儀分析所組成之族 ^種•胃十m魅純誌的方法,其 人類受測者收集—個或多個胃液樣本; 2該-個或多個胃液樣本施行一二維凝膠電 =或多個胃十二指腸疾病特殊之條帶態樣; 匕各具未受疾病感染胃液樣本之二 帶態樣的一個或多個條帶態樣;並 多”刀析條 個或多個分子之異常條帶,該一個 為月十二指腸疾病之生物標誌。 刀子係 8·如申請專利範圍第7項之方法, 病係選自於一包含胃痒、田生/、 μ月”十一指腸疾 合之族群。 广山月潰癌、十二指腸潰瘍和其組 9. 如申請專利範圍第7項 樣本收集自—試驗 ;^亥一個或多個胃液 收線繩之谬囊及其組合所組成之族群。 ,、有吸 10. 如申請專利範圍第7項之 一個哎多個田样士 / 乂已含部份來自 八:弋個月液樣本之分離蛋白質,透過—:自 :選自於-包含贿奈練子蛋 ^ 故、鑽石奈米粒子蛋白f純化試驗、肌 j化試 維凝膠、西方墨點質純化色層分析試驗、二 η.如,請專利範圍第= 之含,。 膠電泳萃取-個或多個分子 36 200817682 多個異常條帶施行質譜分析,其係選自一由 MALDI-TOF質譜分析、電喷霧質譜分析、脫附電喷霧 質譜分析和雷射誘發原聲脫附質譜儀分析所組成之族 群。 12. —種篩選一胃與十二指腸疾病的方法,其包含: 自一人類受測者收集一個或多個胃液樣本; 經由質f普分析於該一個或多個胃液樣本篩選該胃與十 二指腸疾病一個或多個生物標諸的值以產生一個或多 個質譜;並 鑑定該一個或多個生物標誌的異常質量值為該胃或十 二指腸疾病陽性。 13. 如申請專利範圍第12項之方法,其中該胃與十二指 腸疾病係選自於一包含胃癌、胃潰瘍、十二指腸潰瘍及 其組合之族群。 14. 如申請專利範圍第12項之方法,其中基礎線質量值 的質譜係得自一正常、未受疾病感染受測者之胃液。 15. 如申請專利範圍第12項之方法,其中與基礎線值相 較,該異常之質量值係鑑定為一個或多個多肽之抑制 值。 16. 如申請專利範圍第15項之方法,其中該一個或多個 多肽包含選自序列辨識號Nos 1-3之胺基酸序列。 17. 如申請專利範圍第12項之方法,其中與基礎線值相 較,該異常之質量值係鑑定為一個或多個多肽之向上調 控值。 37 200817682 18. 如申請專利範圍第17項之方法,其中該一個或多個 多肽包含選自序列辨識號Nos 4-5之胺基酸序列。 19. 如申請專利範圍第12項之方法,與基礎線值相較, 該異常之質量值係鑑定為一個或多個蛋白質之向上調 控值。 20. 如申請專利範圍第19項之方法,其中該一個或多個 多肽包含一 α-抗胰蛋白酶前驅物。 21. —胃與十二指腸疾病之生物標誌係由申請專利範圍 第1項之方法所鑑定。 22. 申請專利範圍第21項之生物標誌,係包含選自序列 辨識號Nos 1-5之胺基酸序列。 23. —胃與十二指腸疾病之生物標誌係由申請專利範圍 第7項之方法所鑑定。 24. 申請專利範圍第23項之生物標誌,係包含一 α-抗胰 蛋白酶前驅物。 25. —胃癌生物標誌係包含一胺基酸序列,其至少90% 相似於一選自於序列辨識號Nos 1-5之胺基酸序列。 38200817682 X. Patent Application Range: 1. A method for identifying biomarkers of gastric and duodenal diseases, comprising: collecting one or more gastric juice samples from a human subject; performing a mass spectrometry analysis on the one or more gastric fluid samples Generating one or more mass spectra; comparing the mass spectrum of the one or more mass spectra and a baseline quality value; and identifying an abnormal mass value of one or more molecules that are biomarkers of the stomach or duodenal disease . 2. The method of claim 1, wherein the stomach and duodenal disease are selected from the group consisting of gastric cancer, gastric ulcer, duodenal ulcer, and combinations thereof. 3. The method of claim 1, wherein the quality of the baseline quality is obtained from a sample of gastric juice of a normal, unaffected subject. 4. The method of claim 1, wherein the one or more gastric fluid samples are collected from a test selected from the group consisting of endoscopic analysis, a capsule having an absorbent cord, and combinations thereof. 5. The method of claim 1, further comprising separating the protein from the one or more gastric juice samples by a protein purification assay selected from a magnetic nanoparticle-containing protein purification test, diamond nanoparticle Groups of protein purification assays, HPLC protein purification chromatography assays, ion exchange protein purification chromatography assays, two-dimensional gels, Western blots, capillary electrophoresis, and combinations thereof. 6. The method of claim 1, wherein the mass spectrometry is selected from the group consisting of MALDI-TOF mass spectrometry, electrospray ionization mass spectrometry, desorption electrospray 35 200817682 two-spectrum analysis, and thunder (four) acoustic separation (four) spectrometer Analyze the method of the family, the stomach, and the human subjects to collect one or more gastric juice samples; 2 the one or more gastric juice samples to perform a two-dimensional gel electricity = or more a special strip of gastroduodenal diseases; one or more strips of two different patterns of gastric juice samples that are not affected by the disease; and more than one abnormal strip of one or more molecules The one is a biomarker of duodenal diseases. Knife Department 8 · The method of claim 7 is selected from the group consisting of a stomach itch, Tian Sheng /, μ month . Guangshan monthly ulceration, duodenal ulcer and its group 9. If the scope of the patent application is 7th, the sample is collected from the test; the group consisting of one or more gastric juices and the combination of the capsules and their combinations. If there is a suction, 10. If one of the patent applications, item 7 of the 田 田 哎 / / 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂 乂Nai Lizi egg ^, diamond nanoparticle protein f purification test, muscle j test gel, Western ink point purification chromatographic analysis test, two η. For example, please include the scope of the patent =. Gel electrophoresis extraction - one or more molecules 36 200817682 Multiple anomalous bands were subjected to mass spectrometry selected from a MALDI-TOF mass spectrometry, electrospray mass spectrometry, desorption electrospray mass spectrometry and laser induced acoustic sound The population consisting of the desorption mass spectrometer analysis. 12. A method of screening a stomach and duodenal disease, comprising: collecting one or more gastric fluid samples from a human subject; screening the stomach and duodenal disease for the one or more gastric fluid samples via a qualitative analysis Or a plurality of biologically-labeled values to produce one or more mass spectra; and identifying the abnormal mass value of the one or more biomarkers as positive for the stomach or duodenal disease. 13. The method of claim 12, wherein the stomach and duodenal disease is selected from the group consisting of gastric cancer, gastric ulcer, duodenal ulcer, and combinations thereof. 14. The method of claim 12, wherein the mass spectrum of the baseline quality value is obtained from a gastric juice of a normal, unaffected subject. 15. The method of claim 12, wherein the abnormal mass value is identified as a inhibition of one or more polypeptides as compared to a baseline value. 16. The method of claim 15, wherein the one or more polypeptides comprise an amino acid sequence selected from the group consisting of sequence numbers Nos 1-3. 17. The method of claim 12, wherein the quality value of the abnormality is identified as an upwardly regulated value of one or more polypeptides as compared to a baseline value. The method of claim 17, wherein the one or more polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 4-5. 19. If the method of claim 12 is applied, the quality value of the anomaly is identified as an upward adjustment of one or more proteins compared to the baseline value. 20. The method of claim 19, wherein the one or more polypeptides comprise an alpha-antitrypsin precursor. 21. Biomarkers for stomach and duodenal diseases are identified by the method of claim 1 of the scope of the patent application. 22. The biomarker of claim 21, which comprises an amino acid sequence selected from the sequence identification numbers Nos 1-5. 23. The biomarkers of the stomach and duodenal diseases are identified by the method of claim 7 of the scope of the patent application. 24. The biomarker of claim 23, which contains an alpha-antitrypsin precursor. 25. The gastric cancer biomarker comprises an amino acid sequence which is at least 90% similar to an amino acid sequence selected from the sequence number Nos 1-5. 38
TW96129655A 2006-08-14 2007-08-10 Method of gastric juice protein analysis for stomach cancer diagnosis TWI426269B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82231406P 2006-08-14 2006-08-14

Publications (2)

Publication Number Publication Date
TW200817682A true TW200817682A (en) 2008-04-16
TWI426269B TWI426269B (en) 2014-02-11

Family

ID=44769399

Family Applications (2)

Application Number Title Priority Date Filing Date
TW101149612A TWI480552B (en) 2006-08-14 2007-08-10 Method of gastric juice protein analysis for stomach cancer diagnosis
TW96129655A TWI426269B (en) 2006-08-14 2007-08-10 Method of gastric juice protein analysis for stomach cancer diagnosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW101149612A TWI480552B (en) 2006-08-14 2007-08-10 Method of gastric juice protein analysis for stomach cancer diagnosis

Country Status (1)

Country Link
TW (2) TWI480552B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046814A1 (en) 2017-09-01 2019-03-07 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
TWI793238B (en) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 Method and kit of detecting gastrogenic protein in biological sample in vitro
WO2020223646A1 (en) * 2019-05-02 2020-11-05 Creatics Llc Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins

Also Published As

Publication number Publication date
TWI426269B (en) 2014-02-11
TWI480552B (en) 2015-04-11
TW201323877A (en) 2013-06-16

Similar Documents

Publication Publication Date Title
AU2016269481B2 (en) Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
JP6402106B2 (en) Analysis of salivary proteome for gingivitis and periodontitis biomarkers using FT-ICR-MS / MS
CN102687011B (en) Cancer biomarker and the use thereof
JP4834839B2 (en) New diagnostic kit for malignant melanoma
EP3088899B1 (en) Biomarkers for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
KR20120125157A (en) A method for the diagnosis using lectin
WO2013087929A2 (en) Method for identifying marker sequences for gynaecological malignant tumours
Jiang et al. Diagnostic model of saliva peptide finger print analysis of oral squamous cell carcinoma patients using weak cation exchange magnetic beads
WO2004063712A3 (en) Methods for diagnosis and prognosis of cancer
TW200817682A (en) Method of gastric juice protein analysis for stomach cancer diagnosis
Zhou et al. Saliva biomarkers in oral disease
JP6361943B2 (en) Pancreatic cancer diagnostic kit comprising an antibody that specifically binds to complement factor B protein and an antibody that specifically binds to sugar chain antigen 19-9 protein
EP1493034B1 (en) Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity
EP3535587A1 (en) Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients
CN101493464A (en) Molecular marker for breast carcinoma diagnosis
KR101219516B1 (en) Polypeptide markers for the diagnosis of cancers and methods for the diagnosis of cancers using the same
WO2021045180A1 (en) Gastric cancer marker and examination method using same
CN116847859A (en) Methods and uses of microbiome compositions
WO2005116659A2 (en) Compositions and methods relating to alzheimer’s disease
CN110291403B (en) Method for determining BRAF mutations and wild-type BRAF proteins by mass spectrometry
EP3124500A1 (en) Anti-grpr antibody, method for producing same, detection method, use of the antibody, kit and gene construct
KR20110076830A (en) Complement c9 as markers for the diagnosis of small cell lung cancer and non-small cell lung cancer
KR20100083739A (en) Use of complex forms of calmodulin-like skin protein clsp
Liu et al. Peptidome profiles in melamine diet-induced bladder stones in C57BL/6 mice
EP3637106B1 (en) Lung cancer detection method

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees